var title_f12_7_12400="Early gastric cancer UGI";
var content_f12_7_12400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early gastric cancer as seen on upper gastrointestinal (UGI) series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A double contrast upper gastrointestinal study shows a superficial ulcer in the gastric antrum (arrow) with thickened folds radiating towards the ulcer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12400=[""].join("\n");
var outline_f12_7_12400=null;
var title_f12_7_12401="Oxatomide: International drug information";
var content_f12_7_12401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxatomide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cenacert (AR);",
"     </li>",
"     <li>",
"      Cobiona (ES);",
"     </li>",
"     <li>",
"      Danoprox (DE);",
"     </li>",
"     <li>",
"      Dasten (AR);",
"     </li>",
"     <li>",
"      Fensedyl (AR);",
"     </li>",
"     <li>",
"      Oxatokey (ES);",
"     </li>",
"     <li>",
"      Oxetal (HR);",
"     </li>",
"     <li>",
"      Oxleti (ES);",
"     </li>",
"     <li>",
"      Quoxol (ES);",
"     </li>",
"     <li>",
"      Tanzal (ES);",
"     </li>",
"     <li>",
"      Tinset (AR, AT, BE, CZ, DE, FR, GB, HU, IT, LU, MX, NL, PT);",
"     </li>",
"     <li>",
"      Tinset Gel (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Oxatomide Monohydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of allergic rhinitis, chronic urticaria, and conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 30 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Suspension, oral: 2.5 mg/mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10452 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12401=[""].join("\n");
var outline_f12_7_12401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979863\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979856\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979858\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979861\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979857\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821198\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979860\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12402="Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus";
var content_f12_7_12402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12402/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12402/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12402/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/7/12402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise can affect glycemic control in patients treated with both conventional and intensive insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .) The following three cases illustrate some of the problems that can occur with intensive insulin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 32-year-old man usually has well-controlled diabetes. He takes 4 units of lispro and 18 units of detemir before breakfast (9 AM), 2 to 4 units of lispro at lunch (1 PM), and 4 to 8 units of lispro with his evening meal (5 PM). Despite a severe upper respiratory infection, he is determined to follow his usual exercise program. He awakens at 8 AM and has a blood glucose of 298",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    He decides to go for a five mile run before breakfast; he plans to take his morning insulin dose after the run. At that time, he is surprised to find that his blood glucose has risen to 344",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (19.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For",
"    patients who take detemir insulin once a day in the morning, the insulin effect may wear off by 8 or 9 the next morning. Such a patient has little insulin available before exercise; furthermore, the stress of the intercurrent infection in this case will promote the release of counterregulatory hormones (epinephrine, cortisol, and growth hormone) that induce relative insulin resistance. The lack of sufficient insulin effect results in glucose being released from the liver but not being taken up by skeletal muscle. Thus, his blood glucose will rise and he may fatigue easily during the run due to the fall in muscle glucose utilization.",
"   </p>",
"   <p>",
"    It would have been wiser not to run that day. If this were unacceptable, he should have taken some extra lispro insulin before the run (perhaps 6 units, depending upon his usual algorithm). After the run, his blood glucose would probably have been somewhat lower. If it were still above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    he should have taken another 6 units of lispro before breakfast.",
"   </p>",
"   <p>",
"    He should also consider whether he could improve his glycemic control by taking his detemir insulin twice a day or switching to a longer-acting insulin like glargine. However, this change in regimen should not be attempted until he has recovered from the respiratory infection and until he discusses it with his doctor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 45-year-old woman who has had type 1 diabetes for 24 years has noticed frequent hypoglycemic reactions associated with exercise, such as playing golf, aerobics, or cycling. She takes 6 units of regular and 16 units of NPH before breakfast, 6 units of regular before her evening meal, and 10 units of NPH before bedtime. She has tried to prevent hypoglycemia by eating more food. This has led to weight gain but has not prevented symptomatic hypoglycemia during exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of this patient requires answers to the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What time does she exercise and is it approximately the same time each day?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of exercise on blood glucose varies with the prevailing plasma insulin level. When the person is hypoinsulinemic (as often happens after awakening in the morning, before the morning injection), exercise can cause an increase in blood glucose since the glucose released from the liver cannot be taken up by the muscles. On the other hand, exercising shortly after taking an insulin injection may result in faster absorption of the insulin and a rapid decrease in blood glucose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At what site is the insulin injected?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin is absorbed most quickly from the abdomen, more slowly from the arm, and slowest from the leg and buttock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .) The best way to rotate injection sites is to give the morning shot in the abdomen (or arm) and the evening shot in the buttock, but to switch sides and exact locations within these areas.",
"   </p>",
"   <p>",
"    It might also be appropriate to consider an overall reduction in her insulin dose or to reduce the dose in a specific injection in anticipation of upcoming exercise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How vigorously is she treating the hypoglycemic reactions?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low blood glucose levels often lead to a feeling of panic and the intake of excessive amounts of carbohydrate to reverse the reaction. This can have two deleterious effects. First, hyperglycemia may occur for several hours due to the combination of glucose ingestion and glucose released from the liver in response to hypoglycemia. Second, repeated ingestion of extra calories can lead to weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 44-year-old woman is interested in beginning a vigorous exercise program consisting of one hour of racquetball, three times per week, between 9 and 10 PM. Her current insulin regimen consists of 6 units of regular before breakfast, 4 units of regular before lunch, 8 units of regular before dinner, and 10 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    before bedtime.",
"   </p>",
"   <p>",
"    On the first day of her exercise program, her blood glucose before dinner (6 PM) is 124",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    She takes her usual dose of 8 units of regular. Her blood glucose is 145",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before racquetball and 138",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before bedtime. She awakens at 2 AM with a severe hypoglycemic reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles deplete their stores of glycogen during marked exercise. For several hours after exercise, the muscles then take up glucose to replenish the glycogen stores, thereby gradually lowering the blood glucose. To minimize the risk of hypoglycemia, she should reduce her dose of regular before her evening meal by perhaps 4 units and she should take a larger than usual bedtime snack. She can use the postexercise glucose levels to assess the changes induced by exercise and food, thereby allowing her to make appropriate adjustments before her next similar workout.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1806 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.23-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12402=[""].join("\n");
var outline_f12_7_12402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12403="Anal abscess and fistula PI";
var content_f12_7_12403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anal abscess and fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An anal abscess is a mass filled with pus that forms when a gland inside the anus gets infected and clogged. Doctors can find abscesses by inserting a gloved finger into the rectum and feeling for lumps. Some abscesses form fistulas, tunnels that connect the abscess to the outside of the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12403=[""].join("\n");
var outline_f12_7_12403=null;
var title_f12_7_12404="Focal nodular hyperplasia Gross";
var content_f12_7_12404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen showing a mass lesion within a noncirrhotic liver. Note the central stellate scar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank A Mitros, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12404=[""].join("\n");
var outline_f12_7_12404=null;
var title_f12_7_12405="Calcium lactate: Pediatric drug information";
var content_f12_7_12405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium lactate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/38/16996?source=see_link\">",
"    see \"Calcium lactate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16020?source=see_link\">",
"    see \"Calcium lactate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1003104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     200 mg/day of",
"     <b>",
"      elemental calcium",
"     </b>",
"     ; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 50-150 mg/kg/day in 4-6 divided doses; not to exceed 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed in mg of",
"     <b>",
"      calcium lactate",
"     </b>",
"     : 400-500 mg/kg/day divided every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1003120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/16996?source=see_link\">",
"      see \"Calcium lactate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females 19-50 years, males 19-70 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females &ge;51 years, males &ge;71 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Dose expressed as",
"     <b>",
"      elemental calcium",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Adults: 1-2 g or more per day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed as",
"     <b>",
"      calcium lactate",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 400-500 mg/kg/day divided every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 500 mg/kg/day divided every 6-8 hours; maximum daily dose: 9 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 1.5-3 g/day divided every 8 hours; maximum daily dose: 9 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunctive prevention and treatment of osteoporosis:",
"     </b>",
"     Adults: 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     2-3 times/day; recommended dosage includes dietary intake and should be adjusted depending upon the patient&rsquo;s diet; to improve absorption do not administer more than 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 648 mg [equivalent to elemental calcium 84 mg], 650 mg [DSC] [equivalent to elemental calcium 84 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3429878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with plenty of fluids with or following meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3429877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1003105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of calcium deficiency; dietary supplement; adjunctive prevention and treatment of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Constipation, dizziness, dry mouth, headache, hypercalcemia, hypercalciuria, hypomagnesemia, hypophosphatemia, mental confusion, milk-alkali syndrome, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3429094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease; some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1003107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1003116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid ( unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes.  Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3429097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Newborns: 7-12 mg/dL; 0-2 years: 8.8-11.2 mg/dL; 2 years to adults: 9-11 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium, ionized, whole blood: 4.4-5.4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1003117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1003118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3429879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium lactate = 130 mg elemental calcium = 6.5 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12405/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12957 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12405=[""].join("\n");
var outline_f12_7_12405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003104\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442189\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003120\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144706\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144693\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429878\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429877\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003105\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144729\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429094\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429095\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003107\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298942\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144701\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003116\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333870\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429096\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429097\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003117\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003118\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429879\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12957\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12957|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/16996?source=related_link\">",
"      Calcium lactate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16020?source=related_link\">",
"      Calcium lactate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12406="Ethambutol: Drug information";
var content_f12_7_12406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethambutol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/56/8068?source=see_link\">",
"    see \"Ethambutol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"    see \"Ethambutol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myambutol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Etibi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Disseminated",
"     </b>",
"     <b>",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"     </b>",
"     <b>",
"      (MAC) treatment in patients with advanced HIV infection (unlabeled use; ATS/IDSA guidelines, 2007):",
"     </b>",
"     Oral: 15 mg/kg ethambutol in combination with clarithromycin or azithromycin with/without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis, active:",
"     </b>",
"     Oral: FDA-approved labeling: Adolescents &ge;13 years and Adults: Initial: 15 mg/kg once daily (maximum dose: 1.5 g); Retreatment (previous antituberculosis therapy): 25 mg/kg once daily (maximum dose: 2.5 g) for 60 days or until bacteriologic smears and cultures become negative, followed by 15 mg/kg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suggested doses by lean body weight (CDC, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Daily therapy: 15-25 mg/kg (maximum dose: 1.6 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 1600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twice weekly directly observed therapy (DOT): 50 mg/kg (maximum dose: 4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 2800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 4000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Three times/week DOT: 25-30 mg/kg (maximum dose: 2.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     40-55 kg: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     56-75 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     76-90 kg: 2400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen. Treatment regimens consist of an initial 2 month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nontuberculous mycobacterium",
"     </b>",
"     <b>",
"      <i>",
"       (M. kansasii)",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use; ATS/IDSA guidelines, 2007):",
"     </b>",
"     Oral: 15 mg/kg/day ethambutol for duration to include 12 months of culture-negative sputum; typically used in combination with rifampin and isoniazid;",
"     <b>",
"      Note:",
"     </b>",
"     Previous recommendations stated to use 25 mg/kg/day for the initial 2 months of therapy; however, IDSA guidelines state this may be unnecessary given the success of rifampin-based regimens with ethambutol 15 mg/kg/day or omitted altogether.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"      see \"Ethambutol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"     </b>",
"     <b>",
"      (MAC), secondary prophylaxis or treatment: HIV-exposed/-infected:",
"     </b>",
"     Oral: Infants and Children: 15-25 mg/kg/day once daily (maximum: 2.5 g/day) with clarithromycin (or azithromycin) with or without rifabutin (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tuberculosis, active:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen; treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV negative:",
"     </i>",
"     Daily therapy: 15-20 mg/kg/day (maximum: 1 g/day); Twice weekly directly observed therapy (DOT): 50 mg/kg (maximum: 2.5 g/dose) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV-exposed/-infected:",
"     </i>",
"     Daily therapy: 15-25 mg/kg/day (maximum: 2.5 g/day) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and hemodialysis: 15-25 mg/kg/dose 3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Slightly dialyzable (5% to 20%); Administer dose postdialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemofiltration: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-36 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myambutol&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myambutol&reg;: 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary tuberculosis in conjunction with other antituberculosis agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7269849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other mycobacterial diseases in conjunction with other antimycobacterial agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Myambutol&reg; may be confused with Nembutal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, disorientation, dizziness, fever, hallucinations, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, erythema multiforme, exfoliative dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acute gout or hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, GI upset, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, hepatotoxicity (possibly related to concurrent therapy), LFTs abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis; symptoms may include decreased acuity, scotoma, color blindness, or visual defects (usually reversible with discontinuation, irreversible blindness has been described)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Infiltrates (with or without eosinophilia), pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, anaphylactoid reaction; hypersensitivity syndrome (cutaneous reactions, eosinophilia, and organ-specific inflammation)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethambutol or any component of the formulation; optic neuritis (risk vs benefit decision); use in young children, unconscious patients, or any other patient who may be unable to discern and report visual changes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic toxicity: Has been reported, possibly due to concurrent therapy. Monitor liver function prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optic neuritis: May cause optic neuritis (unilateral or bilateral), resulting in decreased visual acuity or other vision changes. Discontinue promptly in patients with changes in vision, color blindness, or visual defects (effects normally reversible, but reversal may require up to a year). Irreversible blindness has been reported. Monitor visual acuity prior to and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Evaluation of visual acuity changes may be more difficult in patients with cataracts, optic neuritis, diabetic retinopathy, and inflammatory conditions of the eye; consideration should be given to whether or not visual changes are related to disease progression or effects of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification recommended. Monitor renal function prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use only in children whose visual acuity can accurately be determined and monitored (not recommended for use in children &lt;13 years of age unless the benefit outweighs the risk).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been seen in animals. There are no adequate and well-controlled studies in pregnant women; there have been reports of ophthalmic abnormalities in infants born to women receiving ethambutol as a component of antituberculous therapy. Use only during pregnancy if benefits outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer suggests use during breast-feeding only if benefits to the mother outweigh the possible risk to the infant. Some references suggest that exposure to the infant is low and does not produce toxicity, and breast-feeding should not be discouraged. Other references recommend if breast-feeding, monitor the infant for rash, malaise, nausea, or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food as absorption is not affected, may cause gastric irritation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ethambutol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $59.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $178.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Myambutol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $57.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $156.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic (monthly) visual testing (each eye individually, as well as both eyes tested together) in patients receiving &gt;15 mg/kg/day; baseline and periodic renal, hepatic, and hematopoietic tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambutol (MY);",
"     </li>",
"     <li>",
"      Arbutol (ID);",
"     </li>",
"     <li>",
"      Bacbutol (ID);",
"     </li>",
"     <li>",
"      Clobutol (PT);",
"     </li>",
"     <li>",
"      Combutol (IN);",
"     </li>",
"     <li>",
"      Dexambutol (FR);",
"     </li>",
"     <li>",
"      E-Butol (SG);",
"     </li>",
"     <li>",
"      Ebutol (SG, TW);",
"     </li>",
"     <li>",
"      Ecox (CO);",
"     </li>",
"     <li>",
"      EMB (DE);",
"     </li>",
"     <li>",
"      EMB-Fatol (HK);",
"     </li>",
"     <li>",
"      Etambutol (BG, BR, HR);",
"     </li>",
"     <li>",
"      Etambutol Northia (AR);",
"     </li>",
"     <li>",
"      Etambutol Richet (AR);",
"     </li>",
"     <li>",
"      Etambutol Richmond (AR);",
"     </li>",
"     <li>",
"      Etapiam (IT);",
"     </li>",
"     <li>",
"      ETH Ciba 400 (ID);",
"     </li>",
"     <li>",
"      Etham (TH);",
"     </li>",
"     <li>",
"      Ethambin-PIN (PH);",
"     </li>",
"     <li>",
"      Ethambutol (PL);",
"     </li>",
"     <li>",
"      Ethbutol (TH);",
"     </li>",
"     <li>",
"      Etibi (AT, ID, IT);",
"     </li>",
"     <li>",
"      Interbutol (PH);",
"     </li>",
"     <li>",
"      Lambutol (TH);",
"     </li>",
"     <li>",
"      Manzida (MX);",
"     </li>",
"     <li>",
"      Myambutol (AT, AU, BE, BF, BJ, CH, CI, DE, DK, ES, ET, FR, GB, GH, GM, GN, GR, IE, IN, KE, KP, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, PK, PT, SC, SD, SE, SL, SN, TH, TN, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Mycobutol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Oributol (FI);",
"     </li>",
"     <li>",
"      Purderal (ZA);",
"     </li>",
"     <li>",
"      Servambutol (PE);",
"     </li>",
"     <li>",
"      Stambutol (FI);",
"     </li>",
"     <li>",
"      Sural (CZ, HN, HU);",
"     </li>",
"     <li>",
"      Tibigon (ID);",
"     </li>",
"     <li>",
"      Tibitol (ID, IN);",
"     </li>",
"     <li>",
"      Tibutol (PE);",
"     </li>",
"     <li>",
"      Tobutol (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout body; concentrated in kidneys, lungs, saliva, and red blood cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: 0%; Inflamed meninges: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (20%) to inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-3.6 hours; End-stage renal disease: 7-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% as unchanged drug, 8% to 15% as metabolites); feces (~20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Addis A, Blowey D, and Koren G, &ldquo;Tuberculosis During Pregnancy,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 1996, 42:1461-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/8792014/pubmed\" id=\"8792014\" target=\"_blank\">",
"        8792014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, &ldquo;Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-6):1-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 52(RR11):3-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ducobu J, DuPont P, Laurent M, et al, &ldquo;Acute Isoniazid/Ethambutol/Rifampicin Overdosage,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8272):632.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al, &ldquo;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2007, 175(4):367-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/17277290/pubmed\" id=\"17277290\" target=\"_blank\">",
"        17277290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(5):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/9929528/pubmed\" id=\"9929528\" target=\"_blank\">",
"        9929528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-20):1-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(11):785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/2124671/pubmed\" id=\"2124671\" target=\"_blank\">",
"        2124671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran JH and Montakantikul P, &ldquo;The Safety of Antituberculosis Medications During Breastfeeding,&rdquo;",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 1998, 14(4):337-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/10205455/pubmed\" id=\"10205455\" target=\"_blank\">",
"        10205455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm\" target=\"_blank\">",
"       file://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm",
"      </a>",
"      . Last accessed February 16, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Tuberculosis in Aging Adults,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1992, 40(2):178-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12406/abstract-text/1740604/pubmed\" id=\"1740604\" target=\"_blank\">",
"        1740604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9430 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-B327878308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12406=[""].join("\n");
var outline_f12_7_12406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168048\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168049\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168087\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168051\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168068\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168052\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168053\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881385\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168024\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168009\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168027\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7269849\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168094\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168085\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168013\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299290\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168018\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168056\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168034\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168035\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168032\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168022\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168036\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168012\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168029\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/56/8068?source=related_link\">",
"      Ethambutol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=related_link\">",
"      Ethambutol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12407="Mitoxantrone: Pediatric drug information";
var content_f12_7_12407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mitoxantrone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"    see \"Mitoxantrone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/4/1094?source=see_link\">",
"    see \"Mitoxantrone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mitoxantrone Injection&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Anthracenedione",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"      see \"Mitoxantrone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Limited data available; further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic leukemia (ALL), relapsed:",
"     </b>",
"     Children and Adolescents: Induction: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 2 days (in combination with other chemotherapeutic agents) (Parker, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute nonlymphocytic leukemias (ANLL):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AML:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Induction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants &lt;1 year:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weight-based dosing: 0.4 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose over 1 hour once daily on days 3-6 for a total of 4 doses (in combination with cytarabine and gemtuzumab) (Aplenc, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA-based dosing: 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1, 3, and 5 (in combination with cytarabine and etoposide) (Gibson, 2011)",
"     <b>",
"      or",
"     </b>",
"     8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days (in combination with cytarabine) (Perel, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children &lt;3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Weight-based dosing: 0.4 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose over 1 hour once daily on days 3-6 for a total of 4 doses (in combination with cytarabine and gemtuzumab) (Aplenc, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA-based dosing: 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 4-5 days (in combination with cytarabine); for incomplete response, may repeat at 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 2 days (in combination with cytarabine) (Perel, 2002; Wells, 2003)",
"     <b>",
"      or",
"     </b>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1, 3, and 5 (in combination with cytarabine and etoposide) (Gibson, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children &ge;3 years and Adolescents: 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 4-5 days (in combination with cytarabine); for incomplete response, may repeat at 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 2 days (in combination with cytarabine) (Perel, 2002; Wells, 2003)",
"     <b>",
"      or",
"     </b>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1, 3, and 5 (in combination with cytarabine and etoposide) (Gibson, 2011)",
"     <b>",
"      or",
"     </b>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 1 hour once daily on days 3-6 for a total of 4 doses (in combination with cytarabine and gemtuzumab) (Aplenc, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Consolidation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Age-directed dosing (Gibson, 2011; Stevens, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Infants &lt;1 year: 7.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Children and Adolescents 1-14 years: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     BSA-directed dosing (Cooper, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA &lt;0.6 m",
"     <sup>",
"      2",
"     </sup>",
"     : 0.4 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose once daily on days 3-6 (in combination with cytarabine and gemtuzumab)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     BSA &ge;0.6 m",
"     <sup>",
"      2",
"     </sup>",
"     : 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 3-6  (in combination with cytarabine and gemtuzumab)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     APL: Consolidation: Children &ge;2 years and Adolescents: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days (Ortega, 2005; Sanz, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute nonlymphocytic leukemias (ANLL):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AML induction: 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat 7-10 days later at 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 2 days (Arlin, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AML consolidation (beginning ~6 weeks after initiation of the final induction course): 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 2 days (in combination with cytarabine), repeat in 4 weeks (Arlin, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3 months; maximum lifetime cumulative dose: 140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (discontinue use with LVEF &lt;50% or clinically significant reduction in LVEF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prostate cancer (advanced hormone-refractory):",
"     </b>",
"     12-14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3 weeks (in combination with corticosteroids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment",
"     </b>",
"     : No dosage adjustment provided in the manufacturer&rsquo;s labeling. Dosage reduction of 50% in patients with serum bilirubin of 1.5-3 mg/dL and dosage reduction of 75% in patients with serum bilirubin &gt;3 mg/dL have been recommended;",
"     <b>",
"      Note:",
"     </b>",
"     MS patients with hepatic impairment should not receive mitoxantrone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANLL patients: Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MS Patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neutrophils &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and LVEF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 2 mg/mL (10 mL, 12.5 mL, 15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13934999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: For I.V. administration only; do not administer by SubQ, I.M., intrathecal, or intra-arterial injection. Must be diluted prior to use; may administer by I.V. bolus over 5-15 minutes or I.V. intermittent infusion over 15-60 minutes. Avoid extravasation; may cause severe local tissue damage if extravasation occurs; pH: 3-4.5",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F197624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, cladribine, etoposide, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, linezolid, melphalan, ondansetron, oxaliplatin, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, aztreonam, cefepime, doxorubicin liposome, pemetrexed, piperacillin/tazobactam, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Paclitaxel.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Opened vials may be stored for 7 days at room temperature or 14 days when refrigerated; solutions diluted for administration are stable for 7 days at room temperature or under refrigeration, although the manufacturer recommends immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute nonlymphocytic leukemias (ANLL; includes myelogenous, promyelocytic, monocytic, and erythroid leukemias); advanced hormone-refractory prostate cancer, secondary progressive, or relapsing-remitting multiple sclerosis (MS) (FDA approved in adults); has also been used for Hodgkin&rsquo;s lymphoma, non-Hodgkin&rsquo;s lymphomas (NHL), acute lymphocytic leukemia (ALL), myelodysplastic syndrome, breast cancer, pediatric acute myelogenous leukemia (AML), pediatric acute promyelocytic leukemia (APL); part of a conditioning regimen for autologous hematopoietic stem-cell transplantation (HSCT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MitoXANtrone may be confused with methotrexate, mitoMYcin, mitotane, Mutamycin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F197623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, cardiac function changes, CHF, ECG changes, edema, hypertension, ischemia, LVEF decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, fatigue, fever, headache, pain, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cutaneous mycosis, nail bed changes, petechiae/bruising, skin infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, hypocalcemia, hyperglycemia, hypokalemia, hyponatremia, menorrhagia, menstrual disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, aphthosis, constipation, diarrhea, dyspepsia, GI bleeding, mucositis, nausea, stomatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Abnormal urine, impotence, sterility, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, granulocytopenia, hemoglobin decreased, hemorrhage, leukopenia, lymphopenia, neutropenia, neutropenic fever, secondary acute leukemias (includes AML, APL),  thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, GGT increased, jaundice, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, proteinuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, pneumonia, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, fungal infection, infection, sepsis (ANLL), systemic infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactoid reactions, anaphylaxis, chest pain, dehydration; extravasation at injection site (may result in burning, erythema, pain, skin discoloration, swelling, or tissue necrosis); interstitial pneumonitis (with combination chemotherapy), hyperuricemia, hypotension, phlebitis at the infusion site, rash, sclera discoloration (blue), tachycardia, urine discoloration (blue-green), urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mitoxantrone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be reduced in patients with pre-existing bone marrow suppression, previous treatment with cardiotoxic agents, and patients with impaired hepatobiliary function. May cause urine, saliva, tears, and sweat to turn blue-green for 24 hours postinfusion; whites of eyes may have blue-green tinge. Should be administered under the supervision of a physician experienced in cancer chemotherapy agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Mitoxantrone can cause severe myelosuppression; use is generally not recommended in patients with pre-existing myelosuppression from prior chemotherapy unless the expected benefit outweighs the risk; do not use if baseline neutrophil count is &lt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     (except for in the treatment of ANLL); monitor blood counts and monitor for infection due to neutropenia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . May cause myocardial toxicity and potentially-fatal heart failure (HF); risk increases with cumulative dosing. Effects may occur during therapy or may be delayed (months or years after completion of therapy). Predisposing factors for mitoxantrone-induced cardiotoxicity include prior anthracycline or anthracenedione therapy, prior cardiovascular disease, concomitant use of cardiotoxic drugs, and mediastinal/pericardial irradiation, although may also occur in patients without risk factors. Prior to therapy initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; and evaluate baseline left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. Not recommended for use in MS patients when LVEF &lt;50%, or baseline LVEF below the lower limit of normal (LLN). Evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) in MS patients prior to each dose and if signs/symptoms of HF develop. Use in MS should be limited to a cumulative dose &le;140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , and discontinued if LVEF falls below LLN or a significant decrease in LVEF is observed; decreases in LVEF and HF have been observed in patients with MS who have received cumulative doses &lt;100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . For I.V. administration only, into a free-flowing I.V.; may cause severe local tissue damage if extravasation occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; extravasation resulting in burning, erythema, pain, swelling, and skin discoloration (blue) has been reported; extravasation may result in tissue necrosis and requires debridement for skin graft. Do not administer SubQ, I.M., or intra-arterial injections (have resulted in local/regional neuropathy); do not administer intrathecally; may cause serious and permanent neurologic damage",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , including local nerve demyelination, seizures, coma, and paraplegia. Hazardous agent; use appropriate precautions for handling and disposal. Secondary acute myelogenous leukemia has been reported in patients treated with mitoxantrone (in both patients with cancer and with MS)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; acute promyelocytic leukemia (APL) has also been observed; symptoms of acute leukemia include excessive bruising, bleeding, and recurrent infections; the risk for secondary leukemia is increased in patients who are heavily pretreated, with higher doses, and with combination chemotherapy; monitor CBC, platelet count; signs and symptoms of infection prior to each course and after discontinuation of mitoxantrone; occurrence of secondary leukemia is more common when anthracyclines are given in combination with DNA-damaging agents, when patients have been heavily pretreated with cytotoxic drugs, or when anthracycline doses have been escalated. Rapid lysis of tumor cells may lead to hyperuricemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Pregnancy should be avoided while on treatment. Women with multiple sclerosis who are of reproductive potential should have a pregnancy test prior to each dose.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, serum uric acid (for leukemia treatment), liver function tests, women with multiple sclerosis of childbearing potential must have a pregnancy test prior to each dose; injection site for signs of extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cardiac monitoring:",
"     </i>",
"     Prior to initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and echocardiogram; evaluate baseline and periodic left ventricular ejection fraction (LVEF) with ECG or multigated radionuclide angiography (MUGA) or MRI. In patients with MS, evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) prior to each dose and if signs/symptoms of HF develop. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA and RNA synthesis by intercalating with DNA and causing template disordering and steric obstruction; replication is decreased by binding to DNA topoisomerase II (enzyme responsible for DNA helix supercoiling); active throughout entire cell cycle. Mitoxantrone inhibits B-cell, T-cell, and macrophage proliferation; impairs antigen presentation and secretion of interferon gamma, TNF",
"     <sub>",
"      &alpha;",
"     </sub>",
"     , IL-2.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into thyroid, liver, pancreas, spleen, heart, bone marrow, and red blood cells; prolonged retention in tissues; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : &gt;1000 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 23-215 hours (median: 75 hours); may be prolonged with liver impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 11% of dose excreted in urine (65% as unchanged drug) and 25% in bile as unchanged drug and metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/4/1094?source=see_link\">",
"      see \"Mitoxantrone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor skin, sclera, tears, sweat, and urine to a blue-green color; women of childbearing potential should be advised to avoid becoming pregnant; contraceptive measures are recommended during therapy; do not breast-feed. Notify physician if fever, chills, sore throat, cough, pain with urinating, trouble breathing, swelling of legs or ankles, uneven or fast heartbeat, or unusual bleeding or bruising occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppression (leukocyte nadir: 10-14 days; recovery: 21 days); injection contains 0.14 mEq of sodium/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aplenc R, Alonzo TA, Gerbing RB, et al, \"Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(14):2390-3295.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/18467731/pubmed\" id=\"18467731\" target=\"_blank\">",
"        18467731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlin Z, Case DC Jr, Moore J, et al, \"Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,\"",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1990, 4(3):177-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/2179638/pubmed\" id=\"2179638\" target=\"_blank\">",
"        2179638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper TM, Franklin J, Gerbing RB, et al, \"AAML03P1, a Pilot Study of the Safety of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Newly Diagnosed Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2012, 118(3):761-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibson BE, Webb DK, Howman AJ, et al, \"Results of a Randomized Trial in Children With Acute Myeloid Leukaemia: Medical Research Council AML12 Trial,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2011, 155(3):366-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/21902686/pubmed\" id=\"21902686\" target=\"_blank\">",
"        21902686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koeller J and Eble M, &ldquo;Mitoxantrone: A Novel Anthracycline Derivative,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(8):574-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/3048848 /pubmed\" id=\"3048848 \" target=\"_blank\">",
"        3048848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JJ, Madero L, Mart&iacute;n G, et al, \"Treatment With All-trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7632-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/16234524/pubmed\" id=\"16234524\" target=\"_blank\">",
"        16234524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker C, Waters R, Leighton C, et al, \"Effect of Mitoxantrone on Outcome of Children With First Relapse of Acute Lymphoblastic Leukaemia (ALL R3): An Open-Label Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9757):2009-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/21131038/pubmed\" id=\"21131038\" target=\"_blank\">",
"        21131038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perel Y, Auvrignon A, Leblanc T, et al, \"Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91. Leuc&aacute;mie Aiq&uuml;e My&eacute;lo&iuml;de Enfant,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2774-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/12065553/pubmed\" id=\"12065553\" target=\"_blank\">",
"        12065553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pratt CB, Vietti TJ, Etcubanas E, et al, &ldquo;Novantrone&reg; for Childhood Malignant Solid Tumors. A Pediatric Oncology Group Phase II Study,&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1986, 4(1):43-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/3700039 /pubmed\" id=\"3700039 \" target=\"_blank\">",
"        3700039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Mart&iacute;n G, Gonz&aacute;lez M, et al, \"Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-trans-retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(4):1237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/14576047/pubmed\" id=\"14576047\" target=\"_blank\">",
"        14576047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens RF, Hann IM, Wheatley K, et al, &ldquo;Marked Improvements in Outcome With Chemotherapy Alone in Paediatric Acute Myeloid Leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial. MRC Childhood Leukaemia Working Party,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1998, 101(1):130-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/9576193/pubmed\" id=\"9576193\" target=\"_blank\">",
"        9576193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells RJ, Adams MT, Alonzo TA, et al, &ldquo;Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(15):2940-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/7/12407/abstract-text/12885813/pubmed\" id=\"12885813\" target=\"_blank\">",
"        12885813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12617 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12407=[""].join("\n");
var outline_f12_7_12407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709094\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197570\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048715\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048707\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197544\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197529\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934999\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048719\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197624\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048710\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048718\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197627\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197623\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048722\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048706\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048705\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197613\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197538\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197540\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197553\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048714\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048704\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048721\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048712\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048723\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=related_link\">",
"      Mitoxantrone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/4/1094?source=related_link\">",
"      Mitoxantrone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12408="Unusual causes of adrenal insufficiency";
var content_f12_7_12408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unusual causes of adrenal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12408/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/7/12408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of primary adrenal insufficiency (Addison's disease) are autoimmune diseases and, to a lesser degree, infections, metastatic disease, and drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other less common disorders can also cause adrenal insufficiency; these conditions will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef52048 \" href=\"UTD.htm?16/57/17308\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADRENOLEUKODYSTROPHY AND ADRENOMYELONEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two phenotypes of this X-linked recessive disorder, which affects 1 in 20,000 males, are characterized by progressive neurologic dysfunction and primary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder may account for as many as 10 percent of all cases of adrenal insufficiency, but can be distinguished from autoimmune adrenalitis by the lack of circulating adrenal autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis is confirmed by measurement of very long chain fatty acids (VLCFAs), which accumulate in all tissues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenoleukodystrophy begins in infancy or childhood with weakness and spasticity and progresses rapidly to dementia, blindness, and quadriparesis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/1,3,4\">",
"       1,3,4",
"      </a>",
"      ]. Adrenal insufficiency may be the only sign of ALD [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adrenomyeloneuropathy begins in adolescence or early adulthood with weakness, spasticity, and distal polyneuropathy, but is milder and progresses more slowly [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neurologic symptoms may appear before adrenal insufficiency, but up to 60 percent of adolescent and young adult men with adrenoleukodystrophy have no or few neurologic abnormalities at the time of diagnosis of adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. Thus, adrenoleukodystrophy or adrenomyeloneuropathy should be considered in any boy or young man with adrenal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild neurologic abnormalities also occur in women who are heterozygous carriers of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/8\">",
"     8",
"    </a>",
"    ]. These women rarely develop adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/9\">",
"     9",
"    </a>",
"    ]. However, they can develop isolated mineralocorticoid insufficiency, as can occur in patients with autoimmune and AIDS-related primary adrenal dysfunction; this is most likely to occur in women taking a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, and treatment of adrenoleukodystrophy are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONGENITAL ADRENAL HYPOPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital adrenal hypoplasia, a condition in which the adrenal cortex does not develop normally, occurs in about 1 of 12,500 births [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/10\">",
"     10",
"    </a>",
"    ]. The disorder usually presents in the neonatal period with one of four forms of primary adrenal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A sporadic form associated with pituitary hypoplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An autosomal recessive form",
"     </li>",
"     <li>",
"      An X-linked cytomegalic form associated with hypogonadotropic hypogonadism",
"     </li>",
"     <li>",
"      An X-linked form associated with glycerol kinase deficiency, psychomotor retardation and, in most patients, Duchenne's muscular dystrophy and a characteristic facies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     X-linked forms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The X-linked forms are caused either by mutations or deletions of a gene, DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia gene on the X chromosome, gene 1), that is located on the short arm of the X chromosome (Xp21) and encodes DAX-1. The Duchenne's muscular dystrophy locus and the glycerol kinase gene are also found in the Xp21 locus and may be deleted as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/16\">",
"     16",
"    </a>",
"    ]. DAX-1, a member of the nuclear hormone receptor gene superfamily, is critical for adrenal and gonadal development. It blocks steroidogenesis by transcriptional silencing of the steroidogenic acute regulatory protein (StAR) promoter and also inhibits the effects of steroidogenic factor 1 (SF-1) on transcription of target genes, including those encoding several CYP steroidogenic enzymes and DAX-1 itself [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DAX-1 is expressed in the affected endocrine tissues: adrenal cortex, gonads, hypothalamus, and pituitary gland [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/18\">",
"     18",
"    </a>",
"    ]. More than 100 DAX-1 mutations have been described, occurring throughout the coding region [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/19\">",
"     19",
"    </a>",
"    ]. While most mutations and large deletions result in severe dysfunction leading to neonatal abnormalities, some missense mutations or single amino acid deletions preserve partial function and can present in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adrenal cortical cells are large and vacuolated like those of the fetal zone; the cortex lacks the permanent zone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/23\">",
"     23",
"    </a>",
"    ]. The clinical presentation is similar to that of salt-wasting P450c21 (CYP21A2, 21-hydroxylase) deficiency (ie, low serum cortisol and aldosterone, high plasma ACTH), but adrenal androgen secretion is not increased and the response of these and other precursors to ACTH stimulation is blunted or absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .) Patients often present in the neonatal period with salt wasting and hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/24\">",
"     24",
"    </a>",
"    ]. In patients who have an additional deletion of the contiguous glycerol kinase gene, the increased serum glycerol concentration may lead to a false report of increased serum triglycerides since the basis for the triglyceride assay is measurement of glycerol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at presentation and severity of adrenal insufficiency are variable, with some patients presenting with neonatal salt-losing crisis, and others, with the X-linked form, presenting later in childhood or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. One patient, with a point mutation, presented with only mineralocorticoid deficiency; several male relatives were unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most individuals develop hypogonadotropic hypogonadism at the time of puberty. It may result from combined hypothalamic, pituitary, and Sertoli cell defects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Secretion of other pituitary hormones is not impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/28\">",
"     28",
"    </a>",
"    ]. Gonadal development is normal, but four patients tested were all azoospermic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/29\">",
"     29",
"    </a>",
"    ]. Human chorionic gonadotropin increases serum testosterone concentrations in most of the patients, but may not stimulate spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/30\">",
"     30",
"    </a>",
"    ]. This suggests that DAX-1 function may be required for spermatogenesis, independent of its known actions in the hypothalamus and pituitary.",
"   </p>",
"   <p>",
"    In contrast, a two-year-old boy with a truncating point mutation in the DAX-1 gene had not only adrenal insufficiency, with very high plasma ACTH concentrations (5000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [1100",
"    <span class=\"nowrap\">",
"     pmol/L]),",
"    </span>",
"    but also gonadotropin-independent precocious puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/31\">",
"     31",
"    </a>",
"    ]. Plasma ACTH and testosterone concentrations and testicular size decreased in response to glucocorticoid therapy. The precocity may have resulted from ACTH activation of melanocortin MCR1 receptors on the Leydig cells.",
"   </p>",
"   <p>",
"    In one study, DAX-1 mutations were found in 58 percent (37 of 64) of 46,XY boys with adrenal insufficiency not attributed to an autoimmune, adrenoleukodystrophy, or congenital adrenal hyperplasia and in all eight boys who also had hypogonadotropic hypogonadism. SF1 mutations causing adrenal failure were found in only two patients with 46,XY gonadal dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who are heterozygous for the DAX-1 gene mutation can be identified; this information may be useful for advising female relatives of affected men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar presentations without DAX-1 mutations have been described.",
"   </p>",
"   <p>",
"    Like DAX-1, SF-1 plays a critical role in adrenal and gonadal development. Studies of 46,XY individuals with abnormal sexual development revealed an SF-1 mutation in 9 of 57 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] without adrenal insufficiency. There was undervirilization of the gonads that included complete sex reversal. However, two patients with XY sex reversal and one with a 46,XX karyotype presented with neonatal adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Thus, it appears that the adrenal gland is less sensitive than the gonads to the dose of an abnormal SF-1 protein.",
"   </p>",
"   <p>",
"    Eighteen patients have been reported with congenital adrenal hypoplasia as well as intrauterine growth restriction, dysmorphic features, metaphyseal dysplasia, and genital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/39\">",
"     39",
"    </a>",
"    ]. The cause of this syndrome, termed IMAGe (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, genital abnormalities) is not known; these patients had neither DAX-1 nor SF-1 mutations. While most of the children presented with adrenal insufficiency in infancy, some did not develop it until the age of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/11,40\">",
"     11,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FAMILIAL GLUCOCORTICOID DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial glucocorticoid deficiency is a rare autosomal recessive disorder in which cortisol and androgen secretion are deficient and unresponsive to ACTH stimulation. Serum cortisol concentrations are low or undetectable and plasma ACTH concentrations are high. Aldosterone secretion is normal or only partially deficient, and responds to postural stimuli and volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disorder usually presents in childhood with hyperpigmentation, muscle weakness, hypoglycemia, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/41\">",
"     41",
"    </a>",
"    ], and may be associated with achalasia and alacrima (Allgrove syndrome, or triple A syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because high intraadrenal cortisol concentrations are necessary for normal adrenomedullary development as well as expression of phenylethanolamine N-methyl transferase, the enzyme that converts norepinephrine to epinephrine in the medulla, patients with isolated familial glucocorticoid deficiency and, presumably, other forms of congenital deficiency of glucocorticoid synthesis or action have extremely low plasma epinephrine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/42\">",
"     42",
"    </a>",
"    ]. This may cause low resting systolic blood pressure and an exaggerated pulse rate response to upright posture, and contribute to fasting hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with isolated familial glucocorticoid deficiency have mutations of the melanocortin-2 (ACTH or MC2R) receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/43\">",
"     43",
"    </a>",
"    ]. Affected individuals may be homozygotes or compound heterozygotes for point mutations that alter a critical amino acid, alter the reading frame, or truncate the ACTH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The mutations either decrease the binding affinity of the receptor for ACTH or reduce the maximal cyclic AMP response, but there is poor correlation between the defects in in vitro binding and signal transduction and clinical severity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with MC2R mutations are considered to have familial glucocorticoid deficiency type 1.",
"   </p>",
"   <p>",
"    Up to 20 percent of patients have mutations in the MRAP gene (melanocortin 2 receptor accessory protein) without mutations of the coding or promoter region of the MC2R receptor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ]. This protein interacts with MC2R and may play a role in trafficking MC2R from the endoplasmic reticulum to the cell surface. These patients are considered to have familial glucocorticoid deficiency type 2.",
"   </p>",
"   <p>",
"    The remaining patients with familial glucocorticoid deficiency do not have a known genetic defect and are referred to as type 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRIPLE A (ALLGROVE SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This rare autosomal recessive genetic disorder is characterized by adrenal insufficiency, achalasia, and alacrima (loss of tears). Many patients with the Allgrove variant also have neurologic disorders, including mental retardation, deafness, peripheral neuropathy, cerebellar ataxia, and autonomic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/43,44,49\">",
"     43,44,49",
"    </a>",
"    ]. Alacrima is usually the earliest sign. Adrenal insufficiency usually occurs in childhood, but has been reported in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Allgrove syndrome have mutations in the AAAS (Alacrima-Achalasia-ACTH-resistant Adrenal insufficiency Syndrome) gene, located on chromosome 12q13, which encodes for the Alacrima-Achalasia-aDrenal Insufficiency Neurologic disorder (ALADIN) protein [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. This protein is part of the WD repeat protein family, which exhibits wide functional diversity that includes protein&ndash;protein interactions, signal transduction, RNA processing, vesicular trafficking, cytoskeleton assembly, and cell division control. Most of the reported mutations produce a truncated protein, although missense and point-mutations have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In one study, patients from families with the same mutation showed significant clinical variability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/53\">",
"     53",
"    </a>",
"    ], and in another, there was little genotype-phenotype correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FAMILIAL GLUCOCORTICOID RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial glucocorticoid resistance is a rare syndrome associated with adrenal hyperplasia. The clinical features are similar to those of CYP11B1 (11-beta-hydroxylase) deficiency, but affected patients do not have glucocorticoid deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=see_link\">",
"     \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathophysiology and genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial glucocorticoid resistance is inherited as an autosomal recessive or dominant disorder characterized by mutations in the glucocorticoid receptor gene, leading to diminished cortisol action and secondary stimulation of ACTH release [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, some patients with clinical and biochemical glucocorticoid resistance have not had mutations in the glucocorticoid-receptor gene, indicating the presence of other defects in the glucocorticoid action [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid receptor defects include decreased steroid binding affinity, defective nuclear binding, and decreased receptor number [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/56\">",
"     56",
"    </a>",
"    ]. Mutant receptors may impair the function of receptors coded by the normal allele by preventing normal dimerization or exerting antagonistic effects on glucocorticoid response elements (GREs), thereby exerting dominant negative effects that result in autosomal dominant expression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/57,59\">",
"     57,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with familial glucocorticoid resistance present in childhood to adulthood with hirsutism, male pattern baldness, and menstrual abnormalities and infertility in women, isosexual precocious puberty, abnormal spermatogenesis and infertility in boys, and with hypertension and hypokalemic alkalosis in both sexes. The clinical presentation varies from asymptomatic to severe. Heterozygotes have mild glucocorticoid resistance but are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/56,57,59\">",
"     56,57,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma ACTH and serum cortisol concentrations are increased in this disorder, but maintain their normal diurnal rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. They are relatively resistant to suppression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Serum concentrations of adrenal androgens (delta-4-androstenedione, dehydroepiandrosterone and its sulfate) and of ACTH-dependent mineralocorticoids (cortisol, corticosterone, and deoxycorticosterone) are also increased because of the chronically elevated plasma ACTH concentration. Serum aldosterone and plasma renin activity tend to be decreased. The adrenal glands appear normal to moderately enlarged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of adrenal insufficiency do not occur in patients with familial glucocorticoid resistance because of the compensatory increases in ACTH and cortisol secretion. The excess of androgens and mineralocorticoid can be ameliorated by the administration of 0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Thiazide diuretics administered alone may cause severe hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/57,61\">",
"     57,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID INSENSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 2.3 percent of normal persons have one of two point mutations in the glucocorticoid receptor gene associated with generalized relative resistance to glucocorticoids, whereas about 6.6 percent have a single point mutation associated with relative hypersensitivity to their action [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/59\">",
"     59",
"    </a>",
"    ]. These individuals have no clinical abnormalities, but may be more or less sensitive to the beneficial effects of glucocorticoid therapy and development of undesirable side-effects. A number of population-based studies suggest an association between various glucocorticoid receptor polymorphisms and modulation of bone mineral density, metabolic syndrome, and depression. At this time, these data are not sufficient to prompt screening for these polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid insensitivity may also be acquired and localized or tissue-specific. Some patients with asthma, for example, fail to respond favorably to prolonged high-dose glucocorticoids but develop serious adverse effects. Fifteen of 17 steroid-resistant asthma patients in one study had reduced glucocorticoid receptor binding affinity that was restricted to T lymphocyte, and the other two had generalized glucocorticoid resistance with decreased receptor number [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/65\">",
"     65",
"    </a>",
"    ]. Receptor binding affinity of normal T-cells can be reduced by incubating them in vitro with the cytokines interleukin-2 and interleukin-4. Thus, glucocorticoid insensitivity may result from uncontrolled immune activation. When an immunosuppressive drug, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A, is combined with a glucocorticoid in treating these patients, their asthma is improved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/59\">",
"     59",
"    </a>",
"    ]. The mechanism by which cytokines decrease glucocorticoid receptor binding affinity is unknown.",
"   </p>",
"   <p>",
"    Acquired localized glucocorticoid insensitivity has also been described in patients with rheumatoid arthritis, AIDS, and lymphoid neoplasms and after organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DEFECTIVE CHOLESTEROL METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cortisol is synthesized from cholesterol provided to the adrenals by circulating low-density lipoproteins (LDL) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/66\">",
"     66",
"    </a>",
"    ] or high-density lipoproteins (HDL) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/67\">",
"     67",
"    </a>",
"    ]. As a result, patients with no LDL, such as those with abetalipoproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/68\">",
"     68",
"    </a>",
"    ], or no LDL receptors, such as those with homozygous familial hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/69\">",
"     69",
"    </a>",
"    ], have a moderately impaired serum cortisol response to ACTH, although they maintain normal basal cortisol secretion and do not have clinically important adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=see_link&amp;anchor=H1983214#H1983214\">",
"     \"Neuroacanthocytosis\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocholesterolemic drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , that inhibit cholesterol biosynthesis at the hydroxy-methylglutaryl (HMG) CoA reductase step do not further impair adrenal function in patients with familial hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12408/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of unusual causes of adrenal insufficiency or resistance to glucocorticoids. These should be considered when the more common causes (autoimmune disease, metastasis, infection, drugs or congenital adrenal hyperplasia) have been excluded.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenoleukodystrophy and adrenomyeloneuropathy, an X-linked disorder, should be considered in any boy or young man with adrenal insufficiency. The diagnosis is confirmed by measurement of very long chain fatty acids (VLCFAs), which accumulate in all tissues.",
"     </li>",
"     <li>",
"      Congenital adrenal hypoplasia should be suspected in neonates with salt wasting and hyperpigmentation. Boys with X-linked forms may also have a failure of puberty (DAX-1). 46,XY individuals with sex reversal or ambiguous genitalia may have SF-1 mutations.",
"     </li>",
"     <li>",
"      Familial glucocorticoid deficiency presents in infancy with low cortisol and high ACTH but normal mineralocorticoid production. About 45 percent are caused by mutations, either in the ACTH receptor or a trafficking protein, MRAP. The cause is not known in 55 percent.",
"     </li>",
"     <li>",
"      IMAGe (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, genital abnormalities) and Triple A syndrome (adrenal insufficiency, achalasia, alacrima and neurologic abnormalities) should be suspected in the context of their additional syndromic features.",
"     </li>",
"     <li>",
"      Patients with familial glucocorticoid resistance present in childhood to adulthood with hirsutism, male pattern baldness, and menstrual abnormalities and infertility in women; isosexual precocious puberty, abnormal spermatogenesis and infertility in boys; and with hypertension and hypokalemic alkalosis in both sexes.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      treatment suppresses the excess androgen and mineralocorticoid production.",
"     </li>",
"     <li>",
"      Patients with acquired or inherited forms of glucocorticoid insensitivity may need additional therapy rather than glucocorticoid alone.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/1\">",
"      Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/2\">",
"      Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J Clin Endocrinol Metab 1998; 83:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/3\">",
"      Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/4\">",
"      Moser HW, Moser AE, Singh I, O'Neill BP. Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol 1984; 16:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/5\">",
"      Laureti S, Casucci G, Santeusanio F, et al. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996; 81:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/6\">",
"      Griffin JW, Goren E, Schaumburg H, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology 1977; 27:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/7\">",
"      Sadeghi-Nejad A, Senior B. Adrenomyeloneuropathy presenting as Addison's disease in childhood. N Engl J Med 1990; 322:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/8\">",
"      Restuccia D, Di Lazzaro V, Valeriani M, et al. Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain 1997; 120 ( Pt 7):1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/9\">",
"      el-Deiry SS, Naidu S, Blevins LS, Ladenson PW. Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. J Clin Endocrinol Metab 1997; 82:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/10\">",
"      Jones D, Kay M, Craigen W, et al. Coal-black hyperpigmentation at birth in a child with congenital adrenal hypoplasia. J Am Acad Dermatol 1995; 33:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/11\">",
"      Lienhardt A, Mas JC, Kalifa G, et al. IMAGe association: additional clinical features and evidence for recessive autosomal inheritance. Horm Res 2002; 57 Suppl 2:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/12\">",
"      Newman NM, Welch E, Challis DR. Adrenal hypoplasia and pituitary agenesis in a normocephalic infant, with a review of the literature. Aust Paediatr J 1988; 24:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/13\">",
"      Wise JE, Matalon R, Morgan AM, McCabe ER. Phenotypic features of patients with congenital adrenal hypoplasia and glycerol kinase deficiency. Am J Dis Child 1987; 141:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/14\">",
"      Stuhrmann M, Heilbronner H, Reis A, et al. Characterisation of a Xp21 microdeletion syndrome in a 2-year-old boy with muscular dystrophy, glycerol kinase deficiency and adrenal hypoplasia congenita. Hum Genet 1991; 86:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/15\">",
"      Scheuerle A, Greenberg F, McCabe ER. Dysmorphic features in patients with complex glycerol kinase deficiency. J Pediatr 1995; 126:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/16\">",
"      Peter M, Viemann M, Partsch CJ, Sippell WG. Congenital adrenal hypoplasia: clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab 1998; 83:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/17\">",
"      Ito M, Yu R, Jameson JL. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Mol Cell Biol 1997; 17:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/18\">",
"      Guo W, Burris TP, McCabe ER. Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis. Biochem Mol Med 1995; 56:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/19\">",
"      Lin L, Achermann JC. Inherited adrenal hypoplasia: not just for kids! Clin Endocrinol (Oxf) 2004; 60:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/20\">",
"      Calvari V, Alpigiani MG, Poggi E, et al. X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism: report on new mutation of the DAX-1 gene in two siblings. J Endocrinol Invest 2006; 29:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/21\">",
"      Tsai WY, Tung YC. Novel deletion mutations of the DAX1 (NR0B1) gene in two Taiwanese families with X-linked adrenal hypoplasia congenita. J Pediatr Endocrinol Metab 2005; 18:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/22\">",
"      Achermann JC, Ito M, Silverman BL, et al. Missense mutations cluster within the carboxyl-terminal region of DAX-1 and impair transcriptional repression. J Clin Endocrinol Metab 2001; 86:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/23\">",
"      Kelch, RP, Virdis, R, Rapaport, R, et al. Congenital adrenal hypoplasia. Pediatr Adolesc Endocrinol 1984; 13:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/24\">",
"      Worley KC, Ellison KA, Zhang YH, et al. Yeast artificial chromosome cloning in the glycerol kinase and adrenal hypoplasia congenita region of Xp21. Genomics 1993; 16:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/25\">",
"      Reutens AT, Achermann JC, Ito M, et al. Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita. J Clin Endocrinol Metab 1999; 84:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/26\">",
"      Verrijn Stuart AA, Ozisik G, de Vroede MA, et al. An amino-terminal DAX1 (NROB1) missense mutation associated with isolated mineralocorticoid deficiency. J Clin Endocrinol Metab 2007; 92:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/27\">",
"      Caron P, Imbeaud S, Bennet A, et al. Combined hypothalamic-pituitary-gonadal defect in a hypogonadic man with a novel mutation in the DAX-1 gene. J Clin Endocrinol Metab 1999; 84:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/28\">",
"      Habiby RL, Boepple P, Nachtigall L, et al. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalmic and pituitary defects in gonadotropin production. J Clin Invest 1996; 98:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/29\">",
"      Mantovani G, De Menis E, Borretta G, et al. DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients. Eur J Endocrinol 2006; 154:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/30\">",
"      Tabarin A, Achermann JC, Recan D, et al. A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000; 105:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/31\">",
"      Domenice S, Latronico AC, Brito VN, et al. Adrenocorticotropin-dependent precocious puberty of testicular origin in a boy with X-linked adrenal hypoplasia congenita due to a novel mutation in the DAX1 gene. J Clin Endocrinol Metab 2001; 86:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/32\">",
"      Lin L, Gu WX, Ozisik G, et al. Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience. J Clin Endocrinol Metab 2006; 91:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/33\">",
"      Schwartz M, Blichfeldt S, M&uuml;ller J. X-linked adrenal hypoplasia in a large Greenlandic family. Detection of a missense mutation (N4401) in the DAX-1 gene; implication for genetic counselling and carrier diagnosis. Hum Genet 1997; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/34\">",
"      K&ouml;hler B, Lin L, Ferraz-de-Souza B, et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat 2008; 29:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/35\">",
"      Lin L, Philibert P, Ferraz-de-Souza B, et al. Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. J Clin Endocrinol Metab 2007; 92:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/36\">",
"      Achermann JC, Ito M, Ito M, et al. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999; 22:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/37\">",
"      Biason-Lauber A, Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 2000; 67:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/38\">",
"      Achermann JC, Ozisik G, Ito M, et al. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin Endocrinol Metab 2002; 87:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/39\">",
"      Tan TY, Jameson JL, Campbell PE, et al. Two sisters with IMAGe syndrome: cytomegalic adrenal histopathology, support for autosomal recessive inheritance and literature review. Am J Med Genet A 2006; 140:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/40\">",
"      Pedreira CC, Savarirayan R, Zacharin MR. IMAGe syndrome: a complex disorder affecting growth, adrenal and gonadal function, and skeletal development. J Pediatr 2004; 144:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/41\">",
"      Spark RF, Etzkorn JR. Absent aldosterone response to ACTH in familial glucocorticoid deficiency. N Engl J Med 1977; 297:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/42\">",
"      Zuckerman-Levin N, Tiosano D, Eisenhofer G, et al. The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: a study in isolated glucocorticoid deficiency. J Clin Endocrinol Metab 2001; 86:5920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/43\">",
"      Stuckey BG, Mastaglia FL, Reed WD, Pullan PT. Glucocorticoid insufficiency, achalasia, alacrima with autonomic motor neuropathy. Ann Intern Med 1987; 106:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/44\">",
"      Clark AJ, Weber A. Adrenocorticotropin insensitivity syndromes. Endocr Rev 1998; 19:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/45\">",
"      Weber A, Toppari J, Harvey RD, et al. Adrenocorticotropin receptor gene mutations in familial glucocorticoid deficiency: relationships with clinical features in four families. J Clin Endocrinol Metab 1995; 80:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/46\">",
"      Elias LL, Huebner A, Pullinger GD, et al. Functional characterization of naturally occurring mutations of the human adrenocorticotropin receptor: poor correlation of phenotype and genotype. J Clin Endocrinol Metab 1999; 84:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/47\">",
"      Heinrichs C, Tsigos C, Deschepper J, et al. Familial adrenocorticotropin unresponsiveness associated with alacrima and achalasia: biochemical and molecular studies in two siblings with clinical heterogeneity. Eur J Pediatr 1995; 154:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/48\">",
"      Chan LF, Clark AJ, Metherell LA. Familial glucocorticoid deficiency: advances in the molecular understanding of ACTH action. Horm Res 2008; 69:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/49\">",
"      Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978; 1:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/50\">",
"      Bentes C, Santos-Bento M, de S&aacute; J, et al. Allgrove syndrome in adulthood. Muscle Nerve 2001; 24:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/51\">",
"      Handschug K, Sperling S, Yoon SJ, et al. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet 2001; 10:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/52\">",
"      Tullio-Pelet A, Salomon R, Hadj-Rabia S, et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000; 26:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/53\">",
"      Sandrini F, Farmakidis C, Kirschner LS, et al. Spectrum of mutations of the AAAS gene in Allgrove syndrome: lack of mutations in six kindreds with isolated resistance to corticotropin. J Clin Endocrinol Metab 2001; 86:5433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/54\">",
"      Houlden H, Smith S, De Carvalho M, et al. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain 2002; 125:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/55\">",
"      Prpic I, Huebner A, Persic M, et al. Triple A syndrome: genotype-phenotype assessment. Clin Genet 2003; 63:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/56\">",
"      Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci 2004; 1024:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/57\">",
"      Lamberts SW, Koper JW, Biemond P, et al. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab 1992; 74:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/58\">",
"      Huizenga NA, de Lange P, Koper JW, et al. Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene. J Clin Endocrinol Metab 2000; 85:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/59\">",
"      Lamberts SW. The glucocorticoid insensitivity syndrome. Horm Res 1996; 45 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/60\">",
"      Chrousos GP, Vingerhoeds A, Brandon D, et al. Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease. J Clin Invest 1982; 69:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/61\">",
"      Lamberts SW, Poldermans D, Zweens M, de Jong FH. Familial cortisol resistance: differential diagnostic and therapeutic aspects. J Clin Endocrinol Metab 1986; 63:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/62\">",
"      Hurley DM, Accili D, Stratakis CA, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/63\">",
"      Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab 2008; 19:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/64\">",
"      van Rossum EF, Feelders RA, van den Beld AW, et al. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am J Med 2004; 117:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/65\">",
"      Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/66\">",
"      Brown MS, Kovanen PT, Goldstein JL. Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog Horm Res 1979; 35:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/67\">",
"      Plump AS, Erickson SK, Weng W, et al. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest 1996; 97:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/68\">",
"      Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982; 54:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/69\">",
"      Illingworth DR, Lees AM, Lees RS. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 1983; 32:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12408/abstract/70\">",
"      Laue L, Hoeg JM, Barnes K, et al. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J Clin Endocrinol Metab 1987; 64:531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 121 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12408=[""].join("\n");
var outline_f12_7_12408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADRENOLEUKODYSTROPHY AND ADRENOMYELONEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONGENITAL ADRENAL HYPOPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      X-linked forms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FAMILIAL GLUCOCORTICOID DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRIPLE A (ALLGROVE SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FAMILIAL GLUCOCORTICOID RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathophysiology and genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GLUCOCORTICOID INSENSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DEFECTIVE CHOLESTEROL METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/57/17308\" title=\"table 1\">",
"      Causes of primary adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=related_link\">",
"      Neuroacanthocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12409="Suspected heart disease in infants and children: Criteria for referral";
var content_f12_7_12409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suspected heart disease in infants and children: Criteria for referral",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Stuart Berger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12409/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Martin I Lorin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12409/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/7/12409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of children with serious congenital heart disease (CHD) are diagnosed during the first four weeks of life, congenital heart disease and acquired heart disease present beyond this time period.",
"   </p>",
"   <p>",
"    The signs and symptoms that lead clinicians to suspect heart disease in infants and children as well as the criteria for referral to a pediatric cardiologist will be reviewed here. Suspected heart disease and criteria for referral in newborns are discussed separately. Specific heart conditions also are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING OF REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although somewhat obvious, the urgency of referral depends on the clinical condition of the patient and the seriousness of the underlying diagnosis that may be suspected.",
"   </p>",
"   <p>",
"    Cardiac disease accounts for a significant number of sudden unexpected deaths in children. In a retrospective review of all autopsies performed at a tertiary Canadian hospital, about 2 percent of deaths were due to sudden unexpected cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12409/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the 103 cases, chart review showed that one-fourth had documented premonitory symptoms. The diagnoses and their relative frequency included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocarditis (36 percent)",
"     </li>",
"     <li>",
"      Hypoplastic left heart syndrome (18 percent)",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy (17 percent)",
"     </li>",
"     <li>",
"      Coronary artery anomalies (6 percent)",
"     </li>",
"     <li>",
"      Aortic stenosis (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urgent referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the newborn period, urgent referral or consultation with a pediatric cardiologist should occur in patients with or at imminent risk for hemodynamic compromise and death due to suspected cardiac disease. Patients with hemodynamic instability, such as those with cardiogenic shock, require immediate care. Other patients who are hemodynamically stable and present with cyanosis, syncope, or tachycardia due to underlying cardiac disease may need urgent cardiac referral or consultation. Patients who require urgent referral should be referred as soon as they are medically stable for transfer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are several different causes of shock, cardiogenic shock should be suspected in any infant or child with a history of heart disease, an abnormal cardiac examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening clinical condition despite fluid resuscitation. These patients require emergent care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac diseases that may present as shock after 4 weeks of age include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myocarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anomalous left coronary artery from the pulmonary artery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link&amp;anchor=H13#H13\">",
"       \"Congenital and pediatric coronary artery abnormalities\", section on 'Variations of coronary artery origin from the pulmonary artery'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Total anomalous pulmonary venous connection with progressive pulmonary venous obstruction in infants (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=see_link\">",
"       \"Total anomalous pulmonary venous connection\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings in patients in shock or with significantly low cardiac output include respiratory distress (tachypnea and wheezing), poor perfusion (deceased capillary refill, cool skin, and decreased distal pulses), and hepatomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central cyanosis, a bluish purple discoloration of tissues (nail beds, tongue, and mucous membranes) is evident when systemic arterial concentration of deoxygenated hemoglobin in the blood exceeds 5",
"    <span class=\"nowrap\">",
"     grams/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which generally corresponds to an oxygen saturation &le;85 percent.",
"   </p>",
"   <p>",
"    Central cyanosis as a presenting sign of congenital heart disease (CHD) is most commonly seen during the first weeks of life in neonates with lesions dependent upon a patent ductus arteriosus (PDA) for pulmonary blood flow. These include critically obstructive right-sided heart lesions (eg, critical pulmonary",
"    <span class=\"nowrap\">",
"     stenosis/atresia,",
"    </span>",
"    tricuspid atresia, and pulmonary atresia with ventricular septal defect). Neonates with critical left-sided obstructive lesions (eg, critical coarctation of the aorta and hypoplastic left syndrome) will present with both shock and cyanosis with ductal closure. In these patients, as the ductus closes, metabolic acidosis, hypotension, pulmonary edema and cyanosis develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707721#H2707721\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Cyanosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyanosis can be a presenting sign of CHD in infants beyond the neonatal period. Cyanosis as a presenting sign of CHD is often accompanied or preceded by signs and symptoms of pulmonary overcirculation (eg, tachypnea, poor feeding, and failure to thrive).",
"   </p>",
"   <p>",
"    The following are some cardiac diseases that may present after 4 weeks of age with a constellation of symptoms that includes cyanosis and those of pulmonary overcirculation, who require urgent referral because of the high-risk of potential cardiac decompensation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Truncus arteriosus.",
"     </li>",
"     <li>",
"      Transposition of the great arteries with a large ventricular septal defect.",
"     </li>",
"     <li>",
"      Complex CHD with single ventricle anatomy. The specific anatomy will dictate the presenting symptoms. For example, patients with a univentricular heart and neither pulmonary or aortic outflow obstruction will present with progressive symptoms of pulmonary overcirculation, heart failure, and cyanosis, especially as the pulmonary vascular resistance drops. Patients with progressive pulmonary stenosis, however, will have worsening cyanosis without signs of pulmonary overcirculation over time, similar to patients with tetralogy of Fallot.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with tetralogy of Fallot may present only with cyanosis and do not have symptoms of overcirculation. In these patients, right ventricular outflow obstruction can fluctuate, which may result in a dynamic increase in right ventricular outflow tract obstruction with a subsequent increase in right-to-left shunt and the development of cyanosis. Patients with tetralogy of Fallot typically have a loud systolic ejection murmur that is heard across the entire precordium and may present with hypercyanotic (\"Tet\") spells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachyarrhythmias, particularly supraventricular tachycardia, may present as either an acute or more insidious episodic event in infants and children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link\">",
"     \"Approach to the child with tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"     \"Management of supraventricular tachycardia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=see_link\">",
"     \"Irregular heart rate (arrhythmias) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is hemodynamically unstable (signs of shock), immediate cardioversion is required.",
"     </li>",
"     <li>",
"      If the patient is hemodynamically stable, urgent cardiac referral or consultation is suggested when the tachycardia is symptomatic (ie, history of poor feeding, lethargy, irritability, respiratory difficulties, and syncope), is accompanied by findings of poor perfusion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has a heart rate greater than 220 beats per minute (bpm) in infants, or greater than 180 bpm in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of childhood syncope, most of which are benign (",
"    <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"     table 1",
"    </a>",
"    ). Syncope is rarely caused by a primary cardiac abnormality, however, cardiac disease that presents as childhood syncope may be life threatening. As a result, cardiac disease must be initially excluded as a cause of childhood syncope. This generally can be done by a thorough history and examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"     \"Emergent evaluation of syncope in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of syncope due to cardiac disease is increased, and urgent referral to a cardiologist is recommended for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope associated with exercise or exertion",
"     </li>",
"     <li>",
"      Recurrent episodes with or without exercise",
"     </li>",
"     <li>",
"      Syncope associated with chest pain",
"     </li>",
"     <li>",
"      Syncope associated with palpitations",
"     </li>",
"     <li>",
"      Syncope in a child with cardiac disease",
"     </li>",
"     <li>",
"      Syncope in a child with a family history of syncope or sudden cardiac death (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H599199#H599199\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Familial SCD'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac diseases that may present as childhood syncope are divided into the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structural and physiologic cardiac disease includes hypertrophic cardiomyopathy, congenital coronary artery abnormalities, pulmonary hypertension, or CHD (eg, aortic stenosis).",
"     </li>",
"     <li>",
"      Electrical abnormalities include long QT and Brugada syndromes, arrhythmogenic right ventricular cardiomyopathy, catecholaminergic paroxysmal ventricular tachycardia, and Wolf-Parkinson-White syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Timely referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timely referral should occur for patients with a suspected cardiac condition that may progress and has the potential to result in hemodynamic compromise, significant morbidity, and even become life threatening over a period of",
"    <span class=\"nowrap\">",
"     weeks/months.",
"    </span>",
"    This referral should occur within days to no longer than a week. These include CHD with left-to-right shunting, such as ventricular septal defects, patent ductus arteriosus, aortopulmonary window, and moderate cases of tetralogy of Fallot, and less commonly, dilated cardiomyopathy, which may be due to tachycardia or ALCAPA. In our center, these patients are generally seen within one week of their presentation.",
"   </p>",
"   <p>",
"    Signs, symptoms, and physical findings suggestive of these cardiac lesions are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Historical features'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Physical findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Routine referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine nonurgent referral is for patients with a potential cardiac lesion that is unlikely to proceed to hemodynamic compromise and can occur over a matter of weeks. These include asymptomatic patients with a loud",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    noninnocent murmur (eg, patients with mild pulmonary or aortic valve stenosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a hemodynamically stable infant, clinical evaluation to assess the likelihood of significant cardiac disease is based upon a thorough history and physical examination. The role of routine electrocardiography (ECG) and pulse oximetry as screening tools for cardiac disease in asymptomatic children is uncertain. Both chest radiography and ECG may be helpful in determining whether there is significant cardiac disease in children in whom cardiac disease is suspected based on historical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical findings.",
"   </p>",
"   <p>",
"    In most infants and children with serious cardiac disease, clinical manifestations present as a constellation of findings rather than one isolated finding. As an example, infants with a significant left-to-right cardiac defect with pulmonary overcirculation (eg, large ventricular septal defect) may present with a history of poor feeding, failure to thrive, respiratory symptoms and grunting, and findings of a loud, harsh holosystolic murmur, tachypnea, and hepatomegaly. Other patients with cardiac disease with less serious consequences may present with a single isolated finding, such as mild aortic stenosis, which presents as a pathologic murmur in an asymptomatic infant or child.",
"   </p>",
"   <p>",
"    The following sections describe clinical features that are suggestive of underlying cardiac disease in a hemodynamically stable child. It is beyond the scope of this discussion to address every specific cardiac defect and the range of its clinical presentation. However, if an infant or child presents with one of these historical features or physical findings, the clinician needs to consider whether or not the underlying cause of these manifestations is due to cardiac disease.",
"   </p>",
"   <p>",
"    If the primary care provider has any question regarding whether referral is appropriate or the timing of referral,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    discuss the patient with a pediatric cardiologist by phone. If there is any question, the patient should be referred.",
"   </p>",
"   <p>",
"    The following specific cardiac lesions are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial septal defects (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"       \"Classification and clinical features of isolated atrial septal defects in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coarctation of the aorta (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital coronary artery abnormalities (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"       \"Congenital and pediatric coronary artery abnormalities\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypoplastic left heart syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=see_link\">",
"       \"Hypoplastic left heart syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Long QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"       \"Diagnosis of congenital long QT syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patent ductus arteriosus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tetralogy of Fallot (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"       \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      D-transposition of the great arteries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Valvar aortic stenosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"       \"Valvar aortic stenosis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular septal defects (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"       \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HISTORICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this section, the historical features suggestive of underlying cardiac disease in a hemodynamically stable infant and child are reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lethargy, irritability, respiratory symptoms (eg, increased rate and work of breathing), and sweating are nonspecific symptoms that are common findings in infants with significant cardiac disease. These symptoms are more common when the infants increase their exertion, such as during feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Poor feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding is one of the most important \"stressors\" that an infant might experience. Although the history is often nonspecific, poor feeding and weight gain are common findings in an infant with significant cardiac disease with limited reserve.",
"   </p>",
"   <p>",
"    The history often elicits the following findings associated with feeding:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lethargy and tiring with early stopping of feeds",
"     </li>",
"     <li>",
"      Respiratory distress with tachypnea, retractions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezing",
"     </li>",
"     <li>",
"      Trouble coordinating feeding and breathing",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Sweating",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor weight gain is due to decreased caloric intake because of poor feeding and increased metabolic demands because of the underlying cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Grunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grunting is defined as a low-pitched sound generated when the infant closes",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    glottis during expiration, which conserves lung volume. Grunting is a nonspecific finding seen in infants with significant pulmonary disease or cardiac abnormalities with poor pulmonary compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is true for infants, nonspecific symptoms are common in children with cardiac disease. These include inability to keep up with peers, respiratory distress and diaphoresis (sweating) especially with exertion, and poor weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although chest pain is one of the more frequent reasons for referral to a pediatric cardiologist, it is infrequently associated with cardiac disease (",
"    <a class=\"graphic graphic_table graphicRef76014 \" href=\"UTD.htm?5/60/6092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, a thorough history and physical examination usually can determine the cause of the chest pain and identify patients who require acute intervention from those who can be managed with reassurance and continued follow-up. Characterizing the chest pain is often helpful in differentiating among the numerous possible underlying etiologies. The chest pain is defined by its time course and duration, quality, location, radiation, severity, precipitating factors, and associated symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=see_link\">",
"     \"Approach to chest pain in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest pain that is suggestive of cardiac disease may have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe and crushing pain that radiates to the arm or jaw is suggestive of cardiac ischemia.",
"     </li>",
"     <li>",
"      Sharp, severe and constant pain that is retrosternal and radiates to the left shoulder is suggestive of pericarditis.",
"     </li>",
"     <li>",
"      Severe, sharp, or \"tearing\" pain that radiates towards the back between the scapulas is suggestive of a dissecting aneurysm.",
"     </li>",
"     <li>",
"      Chest discomfort that is provoked by exertion is suggestive of coronary heart disease or hypertrophic cardiomyopathy.",
"     </li>",
"     <li>",
"      Chest pain associated with syncope or palpitations is suggestive of a tachyarrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with any of the above characteristics require urgent referral to a pediatric cardiologist, as these findings can be associated with life-threatening cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a nonspecific finding in patients with cardiac disease due to systemic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocarditis needs to be considered in a febrile patient with a new or changing heart murmur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatic fever, a sequela of group A streptococcal pharyngitis, can present with myocarditis or pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kawasaki disease (KD) should be considered in any child with a fever greater than five days, particularly if it is accompanied by rash, lymphadenopathy, conjunctivitis, and distal extremity changes. The major complication of KD is coronary artery aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of congenital heart disease (CHD) in a sibling or parent increases the risk of CHD. In one study of adults with disturbances of situs or segmental connection, atrioventricular septal defect, or with tetralogy of Fallot, the infant risk of CHD was 4 percent with an affected parent and was 2 percent with an affected sibling with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12409/abstract/2\">",
"     2",
"    </a>",
"    ]. Other cardiac diseases that have a genetic predisposition include familial dilated cardiomyopathy, hypertrophic cardiomyopathy, and familial causes of sudden cardiac death (eg, long QT syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H599199#H599199\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Familial SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough physical examination should be performed. Key components of the examination to determine whether there is significant cardiac disease include the general appearance and affect of the patient, vital signs (heart rate, blood pressure, and respiratory rate), the respiratory and cardiovascular examination, and the presence of any congenital anomaly or syndrome associated with congenital heart disease (CHD).",
"   </p>",
"   <p>",
"    In this section, the physical findings suggestive of underlying cardiac disease in a hemodynamically stable infant and child are reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia is a nonspecific finding. Cardiac causes of tachycardia include arrhythmias (eg, supraventricular or ventricular tachycardia), heart failure, or left-to-right shunt disease. An electrocardiogram is helpful in evaluating the cause of tachycardia. As discussed, symptomatic patients with tachycardia due to tachyarrhythmias require urgent referral, as they are at-risk for a potentially life-threatening cardiac disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the child with tachycardia\", section on 'Ancillary studies'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Tachyarrhythmias'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=see_link\">",
"     \"Irregular heart rate (arrhythmias) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an elevated blood pressure, repeat measurements should be performed, including blood pressure determination in the lower extremities, to confirm hypertension and rule out coarctation of the aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Failure to thrive",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above in the history, infants with significant heart disease often have poor weight gain because of inadequate intake and increased metabolic demands. Although there are a multitude of causes for failure to thrive (FTT), the possibility of a cardiac cause should be considered in infants who appear to tire easily while feeding, have symptoms of respiratory distress, or who have a loud heart murmur on physical examination.",
"   </p>",
"   <p>",
"    In particular, left-to-right shunt lesions (eg, VSD, PDA, complete atrioventricular (AV) septal defect, or significant AV valve regurgitation) should be considered in infants with FTT and a noninnocent murmur. Cardiomyopathy may present as FTT without an accompanying murmur. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Murmurs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Poor perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor perfusion is manifested by delayed capillary refill (greater than three seconds), cool distal extremities, and decreased peripheral pulses. In patients with cardiac disease, it is typically caused by low cardiac output, which occurs in patients with cardiomyopathy, acute myocarditis, significant left-to-right shunt disease, or left or right ventricular dysfunction due to any etiology.",
"   </p>",
"   <p>",
"    Poor perfusion is also associated with shock or impending shock. Patients with poor perfusion require emergent care. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Cardiogenic shock'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Respiratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although respiratory symptoms are nonspecific, they are a common finding in infants and children with significant cardiac disease. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachypnea is often present in patients with left-to-right shunts or heart failure as a result of increased pulmonary blood flow or pulmonary venous congestion. Retractions may also be seen in patients with pulmonary involvement. Tachypnea and retractions are also seen in patients with severe left heart obstructive abnormalities or cardiomyopathy as a result of elevated left ventricular end-diastolic pressure.",
"     </li>",
"     <li>",
"      Wheezing is usually associated with primary pulmonary disease but may be present in the setting of cardiac disease associated with elevated left ventricular end-diastolic pressure or pulmonary hypertension. Cardiac disease should be considered in the differential diagnosis of any infant with wheezing without an obvious pulmonary cause.",
"     </li>",
"     <li>",
"      Rales are often heard in children with heart failure and pulmonary overcirculation.",
"     </li>",
"     <li>",
"      Stridor may be a manifestation of airway obstruction that is caused by a congenital vascular anomaly, such as a vascular ring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cardiovascular exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac examination begins with palpation. A quiet precordium decreases but does not eliminate the likelihood of cardiac disease.",
"   </p>",
"   <p>",
"    Auscultation is the key component of the cardiac examination and includes assessment of the first and second heart sounds, and detecting the presence of a gallop, friction rib, or heart murmur.",
"   </p>",
"   <p>",
"    Findings that are suggestive of significant heart disease and warrant a referral to a cardiologist include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A loud murmur, Grade 3 or higher",
"     </li>",
"     <li>",
"      Harsh murmur",
"     </li>",
"     <li>",
"      Pansystolic murmur",
"     </li>",
"     <li>",
"      Diastolic murmur",
"     </li>",
"     <li>",
"      A loud or single second heart sound",
"     </li>",
"     <li>",
"      Gallop rhythm",
"     </li>",
"     <li>",
"      Friction rub",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of murmurs in infants and children are innocent murmurs, also referred to as functional murmurs. They are characterized by the following findings that usually differentiate them from pathologic murmurs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Associated with quiet precordium",
"     </li>",
"     <li>",
"      Associated with a normal second heart sound",
"     </li>",
"     <li>",
"      Crescendo-decrescendo pattern",
"     </li>",
"     <li>",
"      Intensity less than grade 3",
"     </li>",
"     <li>",
"      Asymptomatic child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common functional murmur in infants is due to turbulence across the branch pulmonary arteries, which are not fully developed because of the relatively small amount of pulmonary blood flow in utero. It disappears typically by 6 months of age with the increase in size of the branch pulmonary arteries, resulting in a reduction in turbulence. It is characterized by a grade 1 to 2, medium to high-pitched midsystolic ejection murmur heard best at the upper left sternal border, which radiates to the axillae and back.",
"   </p>",
"   <p>",
"    Pathologic murmurs that are associated with specific cardiac defects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonic stenosis &ndash; Harsh systolic ejection murmur at the upper left sternal border",
"     </li>",
"     <li>",
"      Aortic stenosis &ndash; Harsh systolic ejection murmur at the upper right sternal border",
"     </li>",
"     <li>",
"      Ventricular septal defect &ndash; Harsh pansystolic murmur at the left sternal border",
"     </li>",
"     <li>",
"      Patent ductus arteriosus (rarely coronary artery fistula or other collateral blood vessel) &ndash; Continuous murmur",
"     </li>",
"     <li>",
"      Mitral regurgitation &ndash; Blowing, high-pitched systolic murmur at the apex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion on the auscultation of cardiac murmurs is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Second heart sound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of the second heart sound are best heard with the diaphragm of the stethoscope over the second left intercostal space, close to the sternal border. Abnormalities of the second heart sound are suggestive of underlying cardiac disease and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widely split second heart sound is indicative of right ventricular volume overload, and is a common finding in patients with atrial septal defect. It may be hard to appreciate in infants and toddlers because of their faster heart rate and inability to cooperate in the examination.",
"     </li>",
"     <li>",
"      Loud second heart sound is suggestive of pulmonary hypertension, which may be seen in several different congenital cardiac lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Gallop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallop rhythm or constant third heart sound indicates serious heart disease. It may be the first indication of heart failure and is associated with cardiac disease characterized by ventricular dilatation, decreased systolic function, and elevated ventricular diastolic filling pressure. Gallops may be heard in patients with cardiomyopathy, atrio-ventricular incompetent valves, and left-to-right shunt disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Friction rub",
"    </span>",
"    &nbsp;&mdash;&nbsp;Friction rub is an uncommon finding in children and, when present, suggests a diagnosis of pericarditis. It is characterized by a sandpaper-like sound that spans both systole and diastole with no relationship to other heart sounds. It may be accompanied by chest pain, and is usually associated with electrocardiography (ECG) abnormal findings of ST-T wave changes throughout all leads. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Peripheral pulses",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, diminished peripheral pulses may be seen in patients with poor perfusion. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Poor perfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In other circumstances, if only the pulses of the lower extremities are involved, the diagnosis of coarctation of the aorta needs to be considered. In these patients, four-extremity blood pressure measurement should be performed. If the systolic blood pressure in the legs is more than 10 mmHg lower than that measured in the arms, the patient should be referred to a pediatric cardiologist for further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulses may be diminished in the left arm in patients with an aberrant left subclavian artery, which may be a component of a vascular ring. Patients with a vascular ring may present with respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal symptoms or be asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is not a common manifestation of cardiac disease in children, and is rare in infants with CHD. Although periorbital edema may be seen in patients with severe heart disease, it is rarely seen in isolation. Pedal and sacral edema are more commonly associated with renal disease, such as nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link\">",
"     \"Pathophysiology and etiology of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hepatomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;An enlarged liver due to hepatic congestion can result from any cause of right-sided heart failure. The liver edge is typically firm and smooth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Extracardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracardiac abnormalities are frequently detected in children with CHD. Congenital skeletal abnormalities, especially those of the hand and arm, are often associated with cardiac malformations.",
"   </p>",
"   <p>",
"    CHD may be a component of many specific syndromes and chromosomal disorders (",
"    <a class=\"graphic graphic_table graphicRef81423 \" href=\"UTD.htm?25/54/26477\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12409/abstract/3\">",
"     3",
"    </a>",
"    ]. For example, cardiac disease is seen in approximately one-half of individuals with Down syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is a useful and easily obtained study. It is useful in differentiating cardiac disease from pulmonary disease, particularly in patients who present with failure to thrive or grunting, respiratory symptoms, or edema.",
"   </p>",
"   <p>",
"    Important chest radiographic findings include cardiomegaly and increased pulmonary markings in patients with left-to-right shunting, heart failure, pulmonary edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains controversial whether electrocardiography (ECG) is an effective screening tool for the following reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of ECGs will be normal. As a result, ECG screening for cardiac disease may not be cost-effective.",
"     </li>",
"     <li>",
"      Currently, consensus is lacking among pediatric cardiologists with regard to normal ECG guidelines and ECG criteria for referral.",
"     </li>",
"     <li>",
"      Many primary care clinicians who care for children are not comfortable in interpreting the ECG.",
"     </li>",
"     <li>",
"      There are variations in ECG findings based upon age and race. Adult cardiologists, who often interpret pediatric ECGs in the community, may be unfamiliar with age-based variations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is the practice of most pediatric cardiologists not to recommend the routine use of ECG to screen for cardiac disease in infants and children.",
"   </p>",
"   <p>",
"    A systematic review of the literature focused on determining whether there was a role for ECG screening in asymptomatic children for three conditions (hypertrophic cardiomyopathy, long QT syndrome, and Wolff-Parkinson-White syndrome) that are associated with ECG abnormalities and sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12409/abstract/4\">",
"     4",
"    </a>",
"    ]. Although the data demonstrated ECG had a high negative predictive value, there was great variability in the positive predictive value (ie, the likelihood that a patient with a positive test has the disease) because of the use of different criteria and the true prevalence of these conditions.",
"   </p>",
"   <p>",
"    A 2012 policy statement from the American Academy of Pediatrics on sudden cardiac arrest concluded that wide-scale ECG screening would require a major infrastructure change in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12409/abstract/5\">",
"     5",
"    </a>",
"    ]. Although information differentiating between ECG changes found in competitive athletes and those with pathologic conditions have reduced the rate of false positive results, more data are required to help determine the cost-benefit ratio of universal ECG screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Abnormal ECG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG may be helpful in the diagnosis of specific cardiac diseases in an infant or child in whom cardiac disease is suspected based upon the history and physical examination.",
"   </p>",
"   <p>",
"    The following are ECG findings that most pediatric cardiologist would consider abnormal and warrant further investigation. They are divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      True pathological conditions &ndash; ECG findings that directly correlate with true cardiac disease. Patients with these findings should be referred to a pediatric cardiologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wolf-Parkinson-White syndrome &ndash; ECG shows a short PR interval and a delta wave with a wide QRS (",
"      <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"UTD.htm?34/55/35706\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long QT syndrome &ndash; ECG shows a prolongation of the QTc interval of greater than 460 msec (",
"      <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"       waveform 2",
"      </a>",
"      ). The clinician must evaluate this finding in the proper clinical context, as medications can prolong the QTc interval. A family history is also useful in making the diagnosis of congenital long QT syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"       \"Diagnosis of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Second or third degree heart block (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"UTD.htm?42/35/43573\">",
"       waveform 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"       waveform 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link&amp;anchor=H24#H24\">",
"       \"Bradycardia in children\", section on 'AV Heart block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sinus pauses or other sings of sinus node dysfunction (",
"      <a class=\"graphic graphic_waveform graphicRef75018 \" href=\"UTD.htm?3/17/3352\">",
"       waveform 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=see_link\">",
"       \"Sinoatrial nodal pause, arrest, and exit block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial ischemia or inflammation is often associated with abnormal T waves inversions in V5",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      V6, unusual or bizarre T wave morphology (including notched, biphasic, or flat T waves), or ST segment depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=see_link\">",
"       \"ECG tutorial: ST and T wave changes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible pathology &ndash; ECG findings that are suggestive of cardiac disease. In these patients, referral to a pediatric cardiologist should be supported by other findings suggestive of cardiac disease, such as a pathologic cardiac murmur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Left ventricular hypertrophy is suggestive of left heart obstructive lesions, such as aortic stenosis or subaortic stenosis (which should be accompanied by a heart murmur). It is also seen in patients with hypertension, and is a common normal variant in male adolescent athletes.",
"     </li>",
"     <li>",
"      Right ventricular hypertrophy is suggestive of right heart obstructive lesions such as valvar pulmonary stenosis (which should be accompanied by a heart murmur).",
"     </li>",
"     <li>",
"      Left axis deviation is suggestive of an endocardial cushion defect (eg, primum atrial septal defect) that is accompanied by a mitral regurgitation murmur and widely split second heart. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H9#H9\">",
"       \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Primum defects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right axis deviation and right atrial enlargement are suggestive of a secundum atrial septal defect that is often accompanied by a widely split second heart sound and a pulmonary flow murmur. Another ECG finding of incomplete right bundle block is often also seen in patients with a secundum atrial septal defect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H4#H4\">",
"       \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Secundum defects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right bundle branch block or left bundle branch block is most commonly associated with previous cardiac surgery.",
"     </li>",
"     <li>",
"      Intraventricular conduction delay (&gt;0.12 seconds in patients &gt;12 years of age; &gt;0.10 seconds in patients &lt;8 years of age). This may be a variant of normal but may also be associated with right ventricular volume overload as is seen in an atrial septal defect.",
"     </li>",
"     <li>",
"      Atrial, junctional, or ventricular arrhythmias, including frequent premature atrial and ventricular premature contractions, are usually benign, especially in an asymptomatic child with a normal physical examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=see_link\">",
"       \"Irregular heart rate (arrhythmias) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"       \"Causes of wide QRS complex tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Pulse oximetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine use of pulse oximetry to screen for neonatal critical cardiac disease has been shown to be an effective screening test and &nbsp;is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most congenital heart disease (CHD) is diagnosed in the newborn period (first four weeks of life), significant cardiac disease can present anytime throughout infancy and childhood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants and children who are suspected to have heart disease, the timing of referral to a pediatric cardiologist for evaluation and treatment is dependent upon the clinical condition of the patient and the seriousness of the underlying diagnosis that may be suspected.",
"     </li>",
"     <li>",
"      Urgent referral or consultation with a pediatric cardiologist should occur in patients with or at imminent risk for life threatening cardiac disease. This includes patients with cardiogenic shock (who require emergent care) and may include those with cyanosis, syncope, or tachycardia depending upon the clinical context. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Urgent referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough history and physical examination should be performed in hemodynamically stable patients to identify those at risk for significant cardiac disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of referral is based upon the risk (and time course) that the underlying suspected cardiac disease may progress and potentially result in hemodynamic compromise, significant morbidity, and even mortality. If the primary care provider has any question regarding whether referral is appropriate or the timing of referral,",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      should never hesitate to discuss the patient with a pediatric cardiologist by phone. If there is any question, the patient should be referred. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Timing of referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most infants and children with serious cardiac disease, clinical manifestations present as a constellation of findings rather than one isolated finding. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants with cardiac disease, symptoms include nonspecific findings of lethargy, irritability, sweating, grunting, poor feeding, failure to thrive, and respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with cardiac disease, symptoms include nonspecific findings of lethargy, inability to keep up with their peers, and increased respiratory distress and diaphoresis with exertion. Although chest pain is one of the more frequent reasons for referral to a pediatric cardiologist, it is infrequently associated with cardiac disease (",
"      <a class=\"graphic graphic_table graphicRef76014 \" href=\"UTD.htm?5/60/6092\">",
"       table 2",
"      </a>",
"      ). Fever may be seen in patients with cardiac disease due to systemic illness. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of cardiac disease increases if a sibling or parent has a history of congenital cardiac disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key physical findings that are suggestive of underlying childhood cardiac disease include failure to thrive, poor peripheral perfusion, respiratory abnormalities (tachypnea, retractions, wheezes), and cardiac abnormalities (pathologic heart murmur, abnormal second heart sound, gallop, rub, active precordium). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiography may be helpful in identifying cardiac disease. The role of routine electrocardiography (ECG) and pulse oximetry as screening tools is less certain. ECG may be helpful in the diagnosis of specific cardiac diseases in an infant or child in whom cardiac disease is suspected based upon the history and physical examination. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12409/abstract/1\">",
"      Ilina MV, Kepron CA, Taylor GP, et al. Undiagnosed heart disease leading to sudden unexpected death in childhood: a retrospective study. Pediatrics 2011; 128:e513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12409/abstract/2\">",
"      Burn J, Brennan P, Little J, et al. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet 1998; 351:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12409/abstract/3\">",
"      Pierpont ME, Basson CT, Benson DW Jr, et al. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12409/abstract/4\">",
"      Rodday AM, Triedman JK, Alexander ME, et al. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics 2012; 129:e999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12409/abstract/5\">",
"      Section on Cardiology and Cardiac Surgery. Pediatric sudden cardiac arrest. Pediatrics 2012; 129:e1094.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5765 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-C3E2CEE167-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12409=[""].join("\n");
var outline_f12_7_12409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING OF REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urgent referral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cyanosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Timely referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Routine referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HISTORICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Poor feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Grunting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Failure to thrive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Poor perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Respiratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cardiovascular exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Murmurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Second heart sound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Gallop",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Friction rub",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Peripheral pulses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hepatomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Extracardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Abnormal ECG findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37660\" title=\"table 1\">",
"      Causes of syncope children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/60/6092\" title=\"table 2\">",
"      Etiology pediatric chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/54/26477\" title=\"table 3\">",
"      Genetic disorders CV anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5765|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/55/35706\" title=\"waveform 1\">",
"      ECG WPW tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 2\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 3\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29270\" title=\"waveform 4\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/50/13095\" title=\"waveform 5\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/17/3352\" title=\"waveform 6\">",
"      Sinus pause tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=related_link\">",
"      Approach to the child with tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=related_link\">",
"      Irregular heart rate (arrhythmias) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=related_link\">",
"      Sinoatrial nodal pause, arrest, and exit block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=related_link\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12410="Radioiodine in the treatment of hyperthyroidism";
var content_f12_7_12410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radioiodine in the treatment of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12410/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12410/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/7/12410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/7/12410/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/7/12410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30632241\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, radioiodine has been the most popular treatment for hyperthyroidism in the United States. In a 1990 survey, 69 percent of North American thyroid specialists chose radioiodine for a hypothetical patient with Graves' hyperthyroidism. It has been less popular elsewhere, being chosen as first-line therapy for a similar patient by only 22 and 11 percent of European and Japanese thyroid specialists, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly low rates of use were reported in subsequent surveys in the United Kingdom and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radioiodine is administered orally as sodium 131-I in solution or a capsule. The radioiodine is rapidly incorporated into the thyroid and its beta-emissions result in extensive local tissue damage. The net effect is ablation of thyroid function over a period of 6 to 18 weeks.",
"   </p>",
"   <p>",
"    Radioiodine for the treatment of hyperthyroidism will be reviewed here. Other treatment options for Graves' hyperthyroidism and toxic adenoma and toxic multinodular goiter are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .) Radioiodine for nontoxic multinodular goiter is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=see_link\">",
"     \"Diagnostic approach to and treatment of goiter in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632249\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632257\">",
"    <span class=\"h2\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to Graves' hyperthyroidism consists of both rapid amelioration of symptoms with a beta-blocker and measures aimed at decreasing thyroid hormone synthesis with either the administration of a thionamide, radioiodine ablation, or surgery. Radioiodine has been the most popular treatment for hyperthyroidism in the United States, although it is less popular outside of the US [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632264\">",
"    <span class=\"h2\">",
"     Toxic adenoma or multinodular goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon patient preference, either radioiodine therapy or surgery is the treatment of choice for these conditions. An occasional patient can be managed, if preferred or necessary for other reasons, with thionamide drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632271\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632279\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and breastfeeding are absolute",
"    <strong>",
"     contraindications",
"    </strong>",
"    to radioiodine therapy. Fetal thyroid tissue is present by 10 to 12 weeks and would be destroyed by the radioiodine, potentially resulting in cretinism. A pregnancy test should be obtained in women of child-bearing age before the administration of radioiodine.",
"   </p>",
"   <p>",
"    Occasionally, radioiodine is given inadvertently to a pregnant woman [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The infant may be normal, hyperthyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/5\">",
"     5",
"    </a>",
"    ], or hypothyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/6\">",
"     6",
"    </a>",
"    ]. Each possibility should be considered and appropriate action taken immediately after delivery. Alternatively, fetal thyroid function may be assessed in utero by percutaneous umbilical vein sampling after 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid function in the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632286\">",
"    <span class=\"h2\">",
"     Severe ophthalmopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that radioiodine therapy can cause the development or worsening of Graves' ophthalmopathy more often than antithyroid drug therapy or surgery. The changes are often mild and transient, at least in patients who have mild or no ophthalmopathy before therapy. However, many clinicians avoid radioiodine in patients with moderate to severe ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/9\">",
"     9",
"    </a>",
"    ], but not all experts agree that moderate to severe or even advanced ophthalmopathy is an absolute contraindication to radioiodine, if glucocorticoids are given concurrently. We consider severe or sight-threatening ophthalmopathy a relative contraindication to radioiodine therapy.",
"   </p>",
"   <p>",
"    In patients with initially mild ophthalmopathy, worsening after radioiodine therapy may be prevented by the concurrent administration of glucocorticoids. An alternative option for patients with moderate to severe eye disease is to delay treatment with radioiodine until the eye disease has been stable for at least one year. In addition, radioiodine should be used with caution in patients with risk factors for ophthalmopathy, including smoking or a high baseline serum concentration of triiodothyronine (eg, &gt;325",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H30632428\">",
"     'Radioiodine and ophthalmopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632293\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of radioiodine therapy in Graves' disease is to cure the hyperthyroidism. In the past, it was controversial whether radioiodine should be given in a sufficient dose to induce hypothyroidism or a lower dose in an attempt to achieve a euthyroid state [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/11\">",
"     11",
"    </a>",
"    ]. However, due to the high failure rate associated with lower doses designed to leave a patient euthyroid, most experts advocate radioiodine doses that result in hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radioiodine dosing in patients with a toxic adenoma or toxic multinodular goiter (MNG) is less controversial because hypothyroidism is less common after radioiodine treatment of these disorders. Areas of focal autonomy take up radioiodine well, while uptake is limited in adjacent and contralateral thyroid tissue that is suppressed by the hyperthyroid state. As a result, radioiodine tends to destroy only the autonomous areas, and most patients remain euthyroid after radioiodine administration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who develop hypothyroidism usually do so because uptake was not suppressed in the extranodular tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/14\">",
"     14",
"    </a>",
"    ] or because of coexistent chronic lymphocytic thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/10\">",
"     10",
"    </a>",
"    ]. In a few patients with toxic multinodular goiter, radioiodine therapy may evoke the production of TSH-receptor stimulating antibodies, causing recurrent hyperthyroidism (due to Graves&rsquo; disease) several months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of both Graves' disease and toxic",
"    <span class=\"nowrap\">",
"     adenoma/MNG,",
"    </span>",
"    there is debate over whether the dose should be fixed or individualized based upon the size of the thyroid gland and 24-hour radioiodine uptake and turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. The goal of individualized dosing is to maximize cure and minimize the risk of hypothyroidism. However, there are many variables other than thyroid gland size and uptake that may affect treatment outcome. These variables include age, serum thyroxine (T4) concentrations, differences in radiation sensitivity, dietary iodine intake, and previous use of antithyroid drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Data from prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/19\">",
"     19",
"    </a>",
"    ] and randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] do not suggest that individualized regimens based upon elaborate dosimetry are more effective than a fixed dose regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/21\">",
"     21",
"    </a>",
"    ] or a simplified individualized regimen based upon thyroid gland size [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) guidelines for the management of hyperthyroidism recommend a dose (typically 10 to 15 mCi) sufficient to cause hypothyroidism, which can be accomplished equally well with either a fixed or individualized dose regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to individualize the radioiodine dose based upon the size of the thyroid gland and the 24-hour radioiodine uptake. The dose is calculated in microcuries (microCi) or megabecquerels (MBq) per gram (g) of thyroid tissue. We prefer to use higher dose therapy (160 to 200",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    [5.9 to 7.4",
"    <span class=\"nowrap\">",
"     MBq/g]",
"    </span>",
"    for Graves' disease) to ensure successful treatment, and in children and adolescents, to be sure that there is ablation of all thyroid tissue. The doses used to treat toxic adenoma or multinodular goiter are higher than in Graves' disease (about 200",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    [7.4",
"    <span class=\"nowrap\">",
"     MBq/g])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30632314\">",
"     'Dose calculation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632300\">",
"    <span class=\"h2\">",
"     Low versus high",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with Graves' disease, the dose of radioiodine is directly related to the cure rate and the incidence of hypothyroidism. As an example, in a trial of two fixed doses of radioiodine (5 versus 10 millicuries [mCi] equivalent to 185 versus 370 megabecquerels [MBq]) in 813 patients with hyperthyroidism, patients treated with the higher dose had a higher cure rate (85 versus 67 percent) and a higher incidence of hypothyroidism (61 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/23\">",
"     23",
"    </a>",
"    ]. A high dose of radioiodine (128 to 155",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    of thyroid tissue [4.7 to 5.7",
"    <span class=\"nowrap\">",
"     MBq/g])",
"    </span>",
"    cures the hyperthyroidism in 90 percent of patients, but eventually causes hypothyroidism in at least 80 percent, whereas 14 percent have persistent hyperthyroidism requiring additional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/17\">",
"     17",
"    </a>",
"    ]. Administering much higher doses is not associated with higher rates of cure, but may be used in patients who are being retreated after one or more treatment failures, in patients with very large goiters or in patients who have been pretreated with antithyroid drugs, which causes mild radioresistance.",
"   </p>",
"   <p>",
"    Although attempting to lower thyroid function to normal with a low dose of radioiodine may appear desirable, this approach has several disadvantages. In particular, low-dose radioiodine therapy is more likely to result in treatment failure, necessitating another dose in 6 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In addition, less than one-third of patients are euthyroid 10 years after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/26\">",
"     26",
"    </a>",
"    ]. Many patients have chronic subclinical hyperthyroidism, with its associated risks of atrial fibrillation and reduced bone density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When radioiodine is used to treat patients with Graves' hyperthyroidism, we suggest high-dose therapy (160 to 200",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    [5.9",
"    <span class=\"nowrap\">",
"     MBq/g]).",
"    </span>",
"    This will cure the hyperthyroidism and, in most patients, induce hypothyroidism in 12 to 18 weeks. Patients should then be started on full replacement doses of thyroxine (T4) if goiter is absent or slightly lower doses if goiter persists.",
"   </p>",
"   <p>",
"    Traditionally, the doses used to treat toxic adenoma or multinodular goiter are higher than in Graves' disease (about 200",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    [7.4",
"    <span class=\"nowrap\">",
"     MBq/g])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632307\">",
"    <span class=\"h2\">",
"     Fixed versus calculated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a fixed dose of radioiodine simplifies the approach to treatment and is less costly than an individually calculated dose. Fixed doses of 5, 10, or 15 millicuries (mCi; 185, 370, or 555 megabecquerels [MBq]) are commonly given to patients with Graves' hyperthyroidism.",
"   </p>",
"   <p>",
"    Another approach, which we prefer, is to individualize the dose based upon the size of the thyroid gland and the 24-hour radioiodine uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/22\">",
"     22",
"    </a>",
"    ]. One prospective, randomized trial compared a fixed dose with a calculated dose and reported an inverse relationship between therapeutic success and thyroid size in the patients treated with a fixed dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/20\">",
"     20",
"    </a>",
"    ]. Success rates ranged from 100 percent for patients with thyroid volumes &le;15 mL to only 25 percent in patients with volume &ge;75 mL. In another study, a semiquantitative fixed dose regimen - 5 mCi (185 MBq) for patients with small glands, 10 mCi (370 MBq) for those with medium glands, and 15 mCi (555 MBq) for those with large glands - was as effective as more elaborately calculated individual dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/19\">",
"     19",
"    </a>",
"    ]. These data favor an individualized approach to dosing because of the dependence of outcome on gland size.",
"   </p>",
"   <p>",
"    However, other data favor a fixed approach. As an example, in a randomized trial comparing one of four dose methods (low-fixed, high-fixed, low-calculated, high-calculated) in 88 patients with Graves' disease, fixed doses of 6.4 mCi (235 MBq) or 9.4 mCi (350 MBq) were as effective as low or high calculated doses (80 or 120",
"    <span class=\"nowrap\">",
"     microCi/g)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/21\">",
"     21",
"    </a>",
"    ]. After a mean follow-up of 63 months, the majority of patients (57 to 82 percent) were hypothyroid. Hyperthyroidism was present in 18 to 27 percent, and 0 to 19 percent were euthyroid. Clinical outcome was not related to the administered radioiodine dose (hyperthyroid, 334 MBq; euthyroid, 309 MBq; hypothyroid, 334 MBq).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632314\">",
"    <span class=\"h2\">",
"     Dose calculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When calculating the dose of radioiodine to be administered to a patient, we prefer to correct the dose according to the 24-hour uptake. As an example, suppose that one wanted to deliver 160",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    thyroid tissue to a patient whose thyroid gland size was approximately 30 g with a 24-hour uptake of 60 percent. In this patient, the administered dose would be:",
"   </p>",
"   <p>",
"    Dose = (30 g x 160",
"    <span class=\"nowrap\">",
"     microCi/g)",
"    </span>",
"    &divide; 0.60 = 8.0 mCi (296 MBq)",
"   </p>",
"   <p>",
"    This approach requires a trip to the hospital to measure 24-hour radioiodine uptake, but by measuring the uptake just before treatment, the etiology of the hyperthyroidism and the appropriateness of therapy are assured. It has the additional advantage of avoiding undertreatment that can occur when a fixed dose is given to patients with large goiters and low uptakes.",
"   </p>",
"   <p>",
"    Iodine is cleared by the kidneys and therefore dosing of radioiodine in patients with chronic kidney disease, who are receiving hemodialysis, requires consideration. Although the dose of radioiodine is usually reduced in patients with thyroid cancer who are on dialysis, dose adjustments are not necessary in patients receiving radioiodine for hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/27\">",
"     27",
"    </a>",
"    ]. The doses of radioiodine administered for the treatment of hyperthyroidism are much lower than those for thyroid cancer, and a larger fraction of the dose is taken up by the thyroid tissue, requiring less clearance by the kidney immediately after dosing. However, hemodialysis should be performed after the time of maximum uptake in the thyroid, which is approximately 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/28\">",
"     28",
"    </a>",
"    ]. A radiation safety team should be involved with the monitoring of the patient, and the dialysis staff, facility, and equipment. Radiation precautions are required for at least one week after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632321\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach is consistent with the American Thyroid",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Association of Clinical Endocrinologists guidelines for the management of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632329\">",
"    <span class=\"h2\">",
"     Pretreatment with thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine can be administered as initial therapy for hyperthyroidism in most patients with hyperthyroidism, especially if they are receiving adequate therapy with a beta-blocker. However, some patients, particularly older patients or those with comorbidities, are first treated with antithyroid drug therapy until euthyroidism is achieved.",
"   </p>",
"   <p>",
"    The rationale for pretreatment in such patients includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be a transient exacerbation of hyperthyroidism after radioiodine, which is eliminated by pretreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       Methimazole",
"      </a>",
"      returns thyroid function to normal somewhat more rapidly than radioiodine. In one study, for example, thyroid function was normal at a mean of 5.7 weeks after methimazole treatment, while in another study the mean level of T4 was still slightly above normal seven weeks after radioiodine [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. This slightly shorter interval to achieve euthyroidism should not be considered a reason for pretreatment in patients who do not have significant comorbidities, since the side effects and potential toxicity from methimazole are significant.",
"     </li>",
"     <li>",
"      Hyperthyroidism is controlled by 12 weeks in 97 percent of patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      , while 14 percent of patients receiving a single dose of radioiodine fail treatment altogether [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/17,34\">",
"       17,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is disagreement about the benefits and optimal schedule of thionamide administration in patients planning radioiodine therapy. In a meta-analysis of 14 randomized trials, adjunctive use of thionamides administered in the week before, during, or after radioiodine therapy increased the risk of treatment failure (RR 1.28, 95% CI 1.07-1.52) and reduced the risk of hypothyroidism (RR 0.68, 95% CI 0.53-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients who were pretreated with thionamides had a lower incidence of biochemical and clinical hyperthyroidism after radioiodine therapy. The meta-analysis was limited by the poor methodological quality of many of the trials.",
"   </p>",
"   <p>",
"    Controversy remains as to whether pretreatment with PTU is more likely to result in treatment failure than pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    . The meta-analysis did not find a difference between the two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/35\">",
"     35",
"    </a>",
"    ]. However, in two non-randomized trials that compared PTU and methimazole and were not included in the meta-analysis, cure rates after radioiodine in patients receiving PTU were half that of patients receiving methimazole [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of definitive data to support pretreatment or a specific treatment regimen, we prefer to pretreat elderly patients and others who are not tolerating the symptoms of hyperthyroidism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    for four to six weeks before radioiodine. Radioiodine can then be administered once serum thyroid hormone concentrations are in the normal range or after symptoms have subsided. Our practice is to stop methimazole three days before and restart methimazole three days after radioiodine is given. Methimazole is tapered or stopped and thyroid hormone replacement started usually between 4 and 18 weeks following therapy, as determined by thyroid function testing and the reduction in goiter size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3626419\">",
"    <span class=\"h3\">",
"     Candidates for pretreatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elderly patients and others with comorbidities, such as coronary artery disease. These patients may be good candidates for pretreatment because of their vulnerability to the effects of hyperthyroidism.",
"     </li>",
"     <li>",
"      Patients with severe thyrotoxicosis who are not tolerating the symptoms of hyperthyroidism may be good candidates for pretreatment. While pretreatment prolongs the period of intensive treatment, it shortens the period during which patients have many hyperthyroid symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632336\">",
"    <span class=\"h3\">",
"     Stopping thionamides pre-radioiodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thionamides should be discontinued before radioiodine treatment in order to avoid impairing the efficacy of the radioiodine. As an example, in a randomized trial that compared stopping or continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    in 75 patients, the radioiodine treatment was successful in 61 percent of the patients in whom the drug was stopped eight days before radioiodine was administered, as compared with 44 percent in whom methimazole was not discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/38\">",
"     38",
"    </a>",
"    ]. They can be restarted after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632344\">",
"    <span class=\"h3\">",
"     When to stop",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of thionamide discontinuation is uncertain. Most studies suggest that stopping two to three days before radioiodine is optimal. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comparison of the diagnostic and therapeutic radioiodine kinetics in 316 patients treated with radioiodine who did not receive pretreatment before therapy, or in whom it had been stopped for one to two days, found that alterations in uptake, uptake curves, and radioiodine half-life were restored to normal two days after discontinuation of the thiamazole (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      or carbimazole), and that the success rate of the treatment was 87 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study in which thionamides were stopped two days versus seven days prior to radioiodine, post radioiodine free T4 levels were higher in the seven-day group compared to the two-day group, while the 24-hour radioiodine uptakes and the outcome at six months, and one and two years were identical [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found no increases in post radioiodine thyroid hormone concentrations when carbimazole was held for only three days prior to radioiodine administration [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the data described above, our practice is to stop",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    three days before and restart methimazole three days after radioiodine is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632352\">",
"    <span class=\"h2\">",
"     Concurrent treatment with lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    may prolong the retention of radioiodine within the thyroid gland, which could increase the effectiveness of radioiodine therapy. In a retrospective cohort study, the cure rate was slightly higher in patients given lithium (900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 12 days starting five days before radioiodine (91 versus 85 percent; P = 0.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/42\">",
"     42",
"    </a>",
"    ], but there was no difference in a randomized trial of radioiodine alone versus radioiodine plus lithium (900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/43\">",
"     43",
"    </a>",
"    ]. Lithium given coincident with radioiodine can prevent the transient increase in serum thyroid hormone concentrations following radioiodine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/44\">",
"     44",
"    </a>",
"    ]. Because of inconsistent data and the toxicity of lithium, we do not recommend its use in conjunction with radioiodine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=see_link\">",
"     \"Lithium and the thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925861\">",
"    <span class=\"h2\">",
"     Iodine as adjunctive therapy after radioiodine in Graves&rsquo; disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients with Graves&rsquo; disease, where more rapid normalization of thyroid function is essential, super saturated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (SSKI) given daily beginning one week after radioiodine normalizes thyroid function several weeks earlier than in patients given radioiodine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632360\">",
"    <span class=\"h2\">",
"     Low-iodine diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the radioiodine uptake can be increased by following a low iodine diet, this is usually not recommended for patients with hyperthyroidism whose uptakes are frequently quite high on a normal iodine diet. Avoiding iodine containing supplements including most multivitamins for a week prior to treatment, however, may increase uptake and allow for lower administered doses of radioiodine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632367\">",
"    <span class=\"h1\">",
"     POST TREATMENT PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the American Thyroid Association (ATA) published recommendations on radiation safety for patients, families, caregivers, and the public after radioiodine (131-I) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/45\">",
"     45",
"    </a>",
"    ]. The recommendations are based upon clinical experience and available data. However, data on long-term outcomes are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link&amp;anchor=H130958617#H130958617\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\", section on 'Radiation Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The doses of radioiodine administered for the treatment of hyperthyroidism are lower than those used to treat thyroid cancer. The majority of patients with hyperthyroidism can be treated with 131-I in the outpatient setting. As an example, patients receiving doses of up to 55 millicuries (mCi, 2035 megabecquerel [MBq]) for hyperthyroidism can typically be released without exceeding dose limits established by the Nuclear Regulatory Commission (NRC) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link&amp;anchor=H130958638#H130958638\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\", section on 'Patient release criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632375\">",
"    <span class=\"h2\">",
"     Household contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive radioiodine have the potential to expose their home and household contacts via saliva, urine, or radiation emitting from their body. They should be instructed to avoid the following during the restricted period:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sharing cups or utensils",
"     </li>",
"     <li>",
"      Sleeping in the same bed with another adult, pregnant woman, infant, or child",
"     </li>",
"     <li>",
"      Sexual contact",
"     </li>",
"     <li>",
"      Close contact with children and pregnant women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The period of post-treatment precaution varies with the dose administered and retained (",
"    <a class=\"graphic graphic_table graphicRef74105 \" href=\"UTD.htm?14/3/14397\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In the United States, close daytime contact with adults should be avoided for approximately one, two, and five days, and sleeping with another adult should be avoided for approximately three, six, eight, and 11 days for doses of 10, 15, 20, and 30 mCi (370, 555, 740, 1110 MBq), respectively. The period of contact precautions for pregnant partners, infants, and children is longer (one to five days for daytime restrictions and 15 to 23 days for nighttime restrictions).",
"   </p>",
"   <p>",
"    In Europe, where recommended dose to members of the public is less than 1.0 milliSieverts (mSv), these precautions are recommended for one, two, or three weeks, if treated with 5, 10, and 15 mCi (185, 370, 555 MBq), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/47\">",
"     47",
"    </a>",
"    ]. In a survey of household members of patients who received treatment for hyperthyroidism, the dose received by the members was well below the limit of 5.0 mSv recommended by the NRC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632383\">",
"    <span class=\"h2\">",
"     Future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should be delayed four to six months after radioiodine therapy to ensure that hyperthyroidism is successfully cured and hypothyroidism corrected prior to conception. However, unintended pregnancies during this interval should be allowed to proceed to term. Birth defects do not appear to be more common in women treated with radioiodine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/49\">",
"     49",
"    </a>",
"    ]. The gonadal dose is about three rad, similar to that for hysterosalpingography or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/50\">",
"     50",
"    </a>",
"    ]. The estimated risk of genetic damage is 0.005 percent, which is much lower than the spontaneous risk of 0.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632391\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After radioiodine, patients require monitoring for hypothyroidism or persistent or recurrent hyperthyroidism. The percentage of patients who become hypothyroid within the first year after treatment varies directly with the dose of radioiodine. Hypothyroidism occurs in approximately 80 percent of patients receiving high-dose therapy (160",
"    <span class=\"nowrap\">",
"     microCi/g)",
"    </span>",
"    and 10 percent of patients receiving low dose therapy (80",
"    <span class=\"nowrap\">",
"     microCi/g)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/17,25,26\">",
"     17,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothyroidism that develops within the first year may be transient. In a study of 260 patients who received radioiodine therapy for Graves' hyperthyroidism, for example, 67 developed hypothyroidism within the first year after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/52\">",
"     52",
"    </a>",
"    ]. The hypothyroidism was transient in 58 percent. However, 70 percent of those with transient hypothyroidism became permanently hypothyroid in the subsequent 2 to 11 years.",
"   </p>",
"   <p>",
"    Most patients who become euthyroid soon after radioiodine therapy develop hypothyroidism at a rate of 2 to 3 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/25\">",
"     25",
"    </a>",
"    ]. This occurs because of the late effects of radiation and of lymphocytic infiltration and destruction of thyroid tissue, a process similar to chronic lymphocytic (Hashimoto's) thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link&amp;anchor=H10#H10\">",
"     \"Thionamides in the treatment of Graves' disease\", section on 'Mechanism of remission'",
"    </a>",
"    .) Alternatively, patients who become euthyroid after therapy can develop recurrent hyperthyroidism. This occurs because of regrowth of thyroid remnants under continued stimulation of thyrotropin (TSH)-receptor antibodies.",
"   </p>",
"   <p>",
"    The principal test used to follow the immediate effect of treatment of hyperthyroidism is the serum free T4 concentration. Serum T4 should be measured six to eight weeks after radioiodine and then at four to eight week intervals thereafter, depending upon the results of prior testing and change in thyroid size. Measurement of serum TSH can be misleading in the early follow-up period because it can remain low for weeks or even months, even when the patient is biochemically euthyroid or even hypothyroid, with serum free T4 values well within or even below the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. When both TSH and free T4 are low, measurement of serum T3 is necessary to distinguish between persistent hyperthyroidism (T3 elevated) and transient central hypothyroidism (T3 normal or low) associated with recovery of the hypothalamic-pituitary-thyroid axis after treatment of hyperthyroidism. Once steady-state conditions are assured, measurement of serum TSH is required to assess the efficacy of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H10#H10\">",
"     \"Laboratory assessment of thyroid function\", section on 'Monitoring treatment of hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum TSH should be measured at 6- to 12-month intervals for the patient's lifetime because of the ongoing occurrence of hypothyroidism after radioiodine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632413\">",
"    <span class=\"h1\">",
"     RADIOIODINE RESISTANT GRAVES' HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rapid thyroidal iodine turnover whose four-hour radioiodine uptake is higher than the 24-hour radioiodine uptake are more likely to have a poor response to radioiodine treatment. In addition, patients with large, isoechoic glands that have more colloid are more likely to be radioresistant than are hypoechoic glands, which have more densely-packed cells. In one study, treatment failure occurred in 22 percent of patients with isoechoic and 7 percent with hypoechoic glands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with treatment-resistant Graves&rsquo; disease, we typically administer a second larger dose of radioiodine.",
"   </p>",
"   <p>",
"    In one case report, pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    prolonged radioiodine retention and increased the efficacy of radioiodine therapy in a patient with radioiodine resistant Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/56\">",
"     56",
"    </a>",
"    ]. Because of limited data and the potential toxicity of lithium, however, we do not recommend its routine use in patients with radioiodine-resistant Graves' disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632421\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine appears to be quite safe aside from causing hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/51\">",
"     51",
"    </a>",
"    ]. The only definite complication is a 1 percent (or lower) incidence of radiation thyroiditis. It can cause relatively severe thyroid pain that can last two to three weeks and, as noted above, may be associated with exacerbation of hyperthyroidism unless hormone stores were first depleted with thionamide therapy. Nonsteroidal anti-inflammatory drugs are usually sufficient for analgesia, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be required in severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632428\">",
"    <span class=\"h2\">",
"     Radioiodine and ophthalmopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/57-59\">",
"     57-59",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/60-62\">",
"     60-62",
"    </a>",
"    ], studies of patients with Graves' disease suggest that radioiodine therapy is associated with the appearance or exacerbation of ophthalmopathy more often than antithyroid drug therapy or surgery. The changes are often mild and transient, at least in patients who have mild or no ophthalmopathy before therapy. Radioiodine may also be associated with the onset or worsening of infiltrative dermopathy (pretibial myxedema) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=see_link\">",
"     \"Pretibial myxedema in autoimmune thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not known why exacerbation of ophthalmopathy occurs. However, radioiodine therapy is followed by substantial increases in the serum concentrations of antibodies to the",
"    <strong>",
"    </strong>",
"    thyrotropin (TSH) receptor (and other thyroid antigens), which might be important in initiating or exacerbating ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/64\">",
"     64",
"    </a>",
"    ]. The rise in antibody production may be secondary to lack of immune restraint caused by the effect of intrathyroidal radioiodine-induced irradiation on T regulatory cells. The increase in antibody production is not prevented by glucocorticoid therapy for up to seven weeks after radioiodine administration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The important clinical question is whether radioiodine therapy for hyperthyroidism is contraindicated in patients with Graves' disease who also have ophthalmopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632435\">",
"    <span class=\"h3\">",
"     Comparison trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several randomized trials of different antithyroid treatments in patients with Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/57,66,67\">",
"     57,66,67",
"    </a>",
"    ]. In one, ophthalmopathy developed or worsened in 33 percent of the patients treated with radioiodine, as compared with 10 and 16 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    and surgery, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/57\">",
"     57",
"    </a>",
"    ]. This study has been criticized, however, because all of the patients treated with radioiodine became hypothyroid, and treatment with thyroxine was delayed for several months. It is possible that high serum thyrotropin concentrations were in part responsible for the development of ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in another trial, the risk of worsening or new onset ophthalmopathy was higher with radioiodine than antithyroid drugs (39 and 21 percent, respectively), in spite of early treatment of hypothyroidism in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third randomized trial compared treatment with radioiodine (120 to 150",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    of thyroid tissue) alone, radioiodine followed by a three-month course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.4 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for one month, then tapered over two months), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    for 18 months in 443 patients with Graves' hyperthyroidism and slight or no ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/66\">",
"     66",
"    </a>",
"    ]. In the 150 patients treated with radioiodine, 23 (15 percent) either developed or had worsening of ophthalmopathy two to six months after treatment (",
"    <a class=\"graphic graphic_figure graphicRef52658 \" href=\"UTD.htm?17/2/17454\">",
"     figure 1",
"    </a>",
"    ). The change was transient in 15 patients; it persisted in the other eight patients. In comparison, none of the 135 patients treated with radioiodine plus prednisone developed or had worsening of ophthalmopathy, and 50 of the 75 patients (67 percent) with ophthalmopathy improved. In the 148 patients treated with methimazole, three (2 percent) with ophthalmopathy improved, four (3 percent) had worsening, and the other 141 had no change. These patients were closely followed for the development of hypothyroidism and treated immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632443\">",
"    <span class=\"h3\">",
"     Treatment with glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with initially mild ophthalmopathy, worsening after radioiodine therapy may be prevented by the concurrent administration of oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/58,66,69\">",
"     58,66,69",
"    </a>",
"    ]. In one trial, the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight, initiated two to three days prior to radioiodine, continued for one month, and then tapered over two months. In a subsequent retrospective cohort study, a lower starting dose of steroids (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight), with tapering over six weeks, was also shown to be effective in preventing exacerbations of ophthalmopathy in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/70\">",
"     70",
"    </a>",
"    ]. Another retrospective study showed worsening ophthalmopathy in 10 percent of 21 patients treated with oral glucocorticoids and none of the nine patients treated with intravenous glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/71\">",
"     71",
"    </a>",
"    ]. However, only 7 percent of patients who were not given glucocorticoids had progression, suggesting a selection bias.",
"   </p>",
"   <p>",
"    The addition of glucocorticoids to radioiodine has not been studied in patients with severe ophthalmopathy.",
"   </p>",
"   <p>",
"    Many clinicians avoid radioiodine in patients with moderate to severe ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/9\">",
"     9",
"    </a>",
"    ], but not all experts agree that moderate to severe ophthalmopathy is an absolute contraindication to radioiodine, since the risk can be ameliorated with prophylactic steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Radioiodine with glucocorticoids should not be used routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/74\">",
"     74",
"    </a>",
"    ], but should be used in high risk patients who prefer to avoid thyroid surgery or who are intolerant to thionamides. An alternative option is to delay treatment with radioiodine until moderate or severe eye disease has been stable for at least one year. If radioiodine is administered to patients with risk factors for ophthalmopathy, including smoking or a high baseline serum concentration of triiodothyronine (eg, &gt;325",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    careful monitoring for the development or progression of ophthalmopathy is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .) Of note, glucocorticoids reduce the effective thyroidal half-life of radioiodine by increasing renal plasma iodine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/75\">",
"     75",
"    </a>",
"    ]. However, there are no reports that the addition of glucocorticoids reduces the overall effectiveness of radioiodine treatment of the hyperthyroid state.",
"   </p>",
"   <p>",
"    Radioiodine with glucocorticoids has also been used to treat patients with ophthalmopathy who are treated with thyroidectomy. In a small randomized trial, patients with mild to moderate ophthalmopathy receiving a near total thyroidectomy followed by radioiodine ablation had less active ophthalmopathy than those having only a near total thyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/76\">",
"     76",
"    </a>",
"    ]. All patients were treated with intravenous glucocorticoids. These results suggest that although radioiodine might worsen ophthalmopathy when given as primary therapy for hyperthyroidism, total thyroid ablation (near total thyroidectomy followed by radioiodine ablation) may benefit ophthalmopathy.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    after radioiodine therapy does not prevent changes in ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632451\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cooperative Thyrotoxicosis Therapy Follow-up Study Group followed 35,593 patients from 26 centers for cancer mortality after radioiodine therapy. An analysis of data through 1990 representing a mean follow-up of 21 years revealed no increase in overall cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Prolonged follow-up demonstrated a small increase in thyroid cancer risk that was most pronounced in those patients who received radioiodine for toxic nodular goiter (the number of thyroid cancer deaths was small [29 out of a total of 2950 cancer deaths] and the standardized cancer mortality ratio was 2.77, accounting for 18 excess deaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/79\">",
"     79",
"    </a>",
"    ]. Since the risk of thyroid cancer is known to be slightly increased among patients with nodular goiters, it is possible that at least some of the excess thyroid cancer risk is related to underlying thyroid disease.",
"   </p>",
"   <p>",
"    Another analysis of 7417 patients in the United Kingdom also found a significant increase in the incidence of thyroid cancer (nine cases versus three expected) and cancers of the small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/80\">",
"     80",
"    </a>",
"    ]. There was a decrease in the overall cancer incidence (634 cases versus 761 expected). In a study of 2793 Finnish patients, there was an increase in the incidence rate-ratio of cancer risk per 10,000 person-years (1.2 [1.1 to 1.5]) due to cancer of the breast, stomach, and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632459\">",
"    <span class=\"h2\">",
"     Overall mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although radioiodine is safe and effective, some data indicate that it is associated with a slight but significant increase in later mortality, a risk that may be related to hyperthyroidism or long-standing subclinical hyperthyroidism, rather than radioiodine per se [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a long-term study extending over 40 years that included 7209 patients and 105,028 person-years of follow-up, the standardized mortality ratio (SMR) for radioiodine-treated patients was 1.1 (95% CI 1.1-1.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/82\">",
"       82",
"      </a>",
"      ]. Most of the excess deaths occurred during the first year after treatment. The major association at this time was with the hyperthyroidism itself (SMR about 25). Other factors contributing to the excess deaths were total cardiovascular disease and femoral fractures. The data do not permit attribution of the excess deaths specifically to either the hyperthyroidism or the radioiodine.",
"     </li>",
"     <li>",
"      In a second population-based study by the same investigators, 2668 individuals over age 40 years treated with radioiodine for hyperthyroidism (between 1984 and 2002) were examined [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/84\">",
"       84",
"      </a>",
"      ]. A slight excess in mortality was noted in the radioiodine patients compared to age- and period-specific mortality (SMR 1.14, 95% CI 1.04-1.24). However, the increased mortality risk was observed only in patients not requiring thyroid hormone therapy or prior to thyroid hormone replacement. No increased risk was seen during follow-up in patients taking thyroid hormone therapy. Patients with subclinical hypothyroidism (not receiving thyroid hormone) had excess mortality related to ischemic heart disease. These findings suggest that doses of radioiodine for the treatment of hyperthyroidism should be high enough to induce overt hypothyroidism. In addition, thyroid hormone therapy should be considered in patients with subclinical hypothyroidism after radioiodine treatment.",
"     </li>",
"     <li>",
"      A third population-based study of 2793 patients reported an increase in mortality from cerebrovascular disease (RR 1.4), which was felt to be due to the hyperthyroidism per se rather than the radioiodine treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based study of 3888 individuals successfully treated for hyperthyroidism, there was no increase in all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/85\">",
"     85",
"    </a>",
"    ]. The study did not specify the treatment modality.",
"   </p>",
"   <p>",
"    Hospitalization rates for cardiovascular disease may also be higher after radioiodine therapy, as illustrated by a population-based study of 2611 treated patients and 2611 healthy controls. A higher rate of hospitalization for cardiovascular disease was observed in the radioiodine-treated patients (RR 1.12), including atrial fibrillation, cerebrovascular disease, hypertension, and heart failure, which remained elevated for up to 35 years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632467\">",
"    <span class=\"h2\">",
"     Gonadal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine in the doses used to treat hyperthyroidism does not cause infertility or birth defects in the offspring of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30632383\">",
"     'Future pregnancy'",
"    </a>",
"    above.) The total dose to the testes averages 39",
"    <span class=\"nowrap\">",
"     microGy/MBq",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/88\">",
"     88",
"    </a>",
"    ]. Radioiodine administration results in transient reductions in serum testosterone concentrations without change in serum FSH, improved sperm motility (low motility was seen in two-thirds of hyperthyroid patients before radioiodine), and no change in sperm concentration or morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/7/12410/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30632233\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radioiodine can be used for the treatment of hyperthyroidism due to Graves' disease, toxic adenoma, and multinodular goiter.",
"      <strong>",
"      </strong>",
"      Radioiodine is administered orally as sodium 131-I in solution or a capsule. (See",
"      <a class=\"local\" href=\"#H30632249\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radioiodine should",
"      <strong>",
"       not",
"      </strong>",
"      be given to pregnant or lactating women. It is best avoided in patients with severe, active Graves' ophthalmopathy, and if used should be given with concurrent steroids. (See",
"      <a class=\"local\" href=\"#H30632271\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without contraindications, we suggest radioiodine therapy as our first choice for definitive therapy of the hyperthyroidism, given its lower cost and lower complication rate than surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Primary antithyroid drug therapy is an alternative option for patients with mild disease and small goiters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"       \"Treatment of Graves' hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with hyperthyroidism due to a very large or obstructive goiter, we suggest surgery rather than radioiodine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32742?source=see_link\">",
"       \"Treatment of obstructive or substernal goiter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"       \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients being",
"      <strong>",
"      </strong>",
"      treated with radioiodine, we suggest high rather than low dose radioiodine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who are willing to accept a higher risk of treatment failure in return for a reduced risk of hypothyroidism can reasonably choose low dose therapy. We also suggest individualization of the dose based upon the size of the thyroid gland and the 24-hour radioiodine uptake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically administer 160",
"      <span class=\"nowrap\">",
"       microCi/g",
"      </span>",
"      thyroid tissue [5.9",
"      <span class=\"nowrap\">",
"       MBq/g]",
"      </span>",
"      for Graves' hyperthyroidism and 200",
"      <span class=\"nowrap\">",
"       microCi/g",
"      </span>",
"      [7.4",
"      <span class=\"nowrap\">",
"       MBq/g]",
"      </span>",
"      for toxic",
"      <span class=\"nowrap\">",
"       adenoma/MNG.",
"      </span>",
"      A fixed dose of 10 to 15 mCi [370 to 555 MBq] for Graves and 15 to 20 mCi [500 to 740 MBq] for toxic",
"      <span class=\"nowrap\">",
"       adenoma/MNG",
"      </span>",
"      is an alternative option, although higher fixed doses should be used for larger glands. (See",
"      <a class=\"local\" href=\"#H30632314\">",
"       'Dose calculation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with significant symptoms of hyperthyroidism and in elderly patients with underlying cardiac disease, we suggest starting a thionamide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ) to achieve euthyroidism prior to radioiodine therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We discontinue methimazole three days prior to radioiodine and restart three days after radioiodine therapy. For young and middle-aged patients who are less symptomatic, there is no need to pretreat with a thionamide, and radioiodine can be given soon after the diagnosis is made. (See",
"      <a class=\"local\" href=\"#H30632329\">",
"       'Pretreatment with thionamides'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"       \"Thionamides in the treatment of Graves' disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/1\">",
"      Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/2\">",
"      Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf) 2008; 68:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/3\">",
"      Walsh JP. Management of Graves' disease in Australia. Aust N Z J Med 2000; 30:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/4\">",
"      Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/5\">",
"      Evans PM, Webster J, Evans WD, et al. Radioiodine treatment in unsuspected pregnancy. Clin Endocrinol (Oxf) 1998; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/6\">",
"      Berg GE, Nystr&ouml;m EH, Jacobsson L, et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 1998; 39:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/7\">",
"      Welch CR, Hocking M, Franklyn JA, Whittle MJ. Fetal thyrotrophin: the best indicator of long term thyroid function after in utero exposure to iodine-131? Fetal Diagn Ther 1998; 13:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/8\">",
"      Thorpe-Beeston JG, Nicolaides KH, McGregor AM. Fetal thyroid function. Thyroid 1992; 2:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/9\">",
"      Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/10\">",
"      Mariotti S, Martino E, Francesconi M, et al. Serum thyroid autoantibodies as a risk factor for development of hypothyroidism after radioactive iodine therapy for single thyroid 'hot' nodule. Acta Endocrinol (Copenh) 1986; 113:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/11\">",
"      Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/12\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/13\">",
"      Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984; 101:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/14\">",
"      Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 1983; 309:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/15\">",
"      Nygaard B, Faber J, Veje A, et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 1999; 9:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/16\">",
"      Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag 2010; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/17\">",
"      Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/18\">",
"      Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf) 2007; 66:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/19\">",
"      Jarl&oslash;v AE, Heged&uuml;s L, Kristensen LO, et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995; 43:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/20\">",
"      Peters H, Fischer C, Bogner U, et al. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/21\">",
"      Leslie WD, Ward L, Salamon EA, et al. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003; 88:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/22\">",
"      Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 1991; 35:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/23\">",
"      Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/24\">",
"      Rapoport B, Caplan R, DeGroot LJ. Low-dose sodium iodide I 131 therapy in Graves disease. JAMA 1973; 224:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/25\">",
"      Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/26\">",
"      Sridama V, McCormick M, Kaplan EL, et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984; 311:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/27\">",
"      Holst JP, Burman KD, Atkins F, et al. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005; 15:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/28\">",
"      Nibhanupudy JR, Hamilton W, Sridhar R, et al. Iodine-131 treatment of hyperthyroidism in a patient on dialysis for chronic renal failure. Am J Nephrol 1993; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/29\">",
"      Shafer RB, Nuttall FQ. Acute changes in thyroid function in patients treated with radioactive iodine. Lancet 1975; 2:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/30\">",
"      Burch HB, Solomon BL, Cooper DS, et al. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab 2001; 86:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/31\">",
"      Stensvold AD, Jorde R, Sundsfjord J. Late and transient increases in free T4 after radioiodine treatment for Graves' disease. J Endocrinol Invest 1997; 20:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/32\">",
"      Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/33\">",
"      Ross DS, Daniels GH, De Stefano P, et al. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/34\">",
"      Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007; 92:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/35\">",
"      Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007; 334:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/36\">",
"      Imseis RE, Vanmiddlesworth L, Massie JD, et al. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/37\">",
"      Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004; 14:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/38\">",
"      Bonnema SJ, Bennedbaek FN, Veje A, et al. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab 2006; 91:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/39\">",
"      Dunkelmann S, Kuenstner H, Nabavi E, et al. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease. Eur J Nucl Med Mol Imaging 2007; 34:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/40\">",
"      Kubota S, Ohye H, Yano G, et al. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease. Endocr J 2006; 53:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/41\">",
"      Walter MA, Christ-Crain M, Schindler C, et al. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 2006; 33:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/42\">",
"      Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 2010; 95:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/43\">",
"      Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 2002; 12:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/44\">",
"      Bogazzi F, Bartalena L, Campomori A, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2002; 87:4490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/45\">",
"      American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid 2011; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     United States Nuclear Regulatory Commission (NRC). Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Medical Use Licenses, 2008. file://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-36 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/47\">",
"      Mathieu I, Caussin J, Smeesters P, et al. Doses in family members after 131I treatment. Lancet 1997; 350:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/48\">",
"      Beckers C. Regulations and policies on radioiodine 131I therapy in Europe. Thyroid 1997; 7:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/49\">",
"      Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975; 292:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/50\">",
"      Robertson JS, Gorman CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 1976; 17:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/51\">",
"      Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986; 105:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/52\">",
"      Aizawa Y, Yoshida K, Kaise N, et al. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol (Oxf) 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/53\">",
"      Davies PH, Franklyn JA, Daykin J, Sheppard MC. The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine. J Clin Endocrinol Metab 1992; 74:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/54\">",
"      Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 1995; 99:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/55\">",
"      Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2007; 92:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/56\">",
"      Hoogenberg K, Beentjes JA, Piers DA. Lithium as an adjunct to radioactive iodine in treatment-resistant Graves thyrotoxicosis. Ann Intern Med 1998; 129:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/57\">",
"      Tallstedt L, Lundell G, T&oslash;rring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/58\">",
"      Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/59\">",
"      Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994; 79:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/60\">",
"      Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/61\">",
"      Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA 1982; 247:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/62\">",
"      Perros P, Kendall-Taylor P, Neoh C, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 2005; 90:5321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/63\">",
"      Harvey RD, Metcalfe RA, Morteo C, et al. Acute pre-tibial myxoedema following radioiodine therapy for thyrotoxic Graves' disease. Clin Endocrinol (Oxf) 1995; 42:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/64\">",
"      McGregor AM, Petersen MM, Capiferri R, et al. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease. Clin Endocrinol (Oxf) 1979; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/65\">",
"      Gamstedt A, Wadman B, Karlsson A. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. J Clin Endocrinol Metab 1986; 62:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/66\">",
"      Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/67\">",
"      Tr&auml;isk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94:3700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/68\">",
"      Wartofsky L. Therapeutic controversies. Summation, commentary, and overview: concerns over aggravation of Graves' ophthalmopathy by radioactive iodine treatment and the use of retrobulbar radiation therapy. J Clin Endocrinol Metab 1995; 80:347.",
"     </a>",
"    </li>",
"    <li>",
"     Lai, A, Sassi, L, Compri, E, et al. Lower Dose Prednisone Prevents Radioiodine-Associated Exacerbation of Initially Mild or Absent Graves' Orbitopathy: A Retrospective Cohort Study. J Clin Endocrinol Metab 2010; 95:1333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/70\">",
"      Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010; 95:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/71\">",
"      Vannucchi G, Campi I, Covelli D, et al. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009; 94:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/72\">",
"      Gorman CA. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/73\">",
"      Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011; 96:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/74\">",
"      Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998; 338:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/75\">",
"      Hautzel H, Pisar E, Yazdan-Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. J Nucl Med 2010; 51:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/76\">",
"      Menconi F, Marin&ograve; M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007; 92:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/77\">",
"      Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study. JAMA 1968; 205:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/78\">",
"      Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998; 280:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/79\">",
"      Dobyns BM, Sheline GE, Workman JB, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/80\">",
"      Franklyn JA, Maisonneuve P, Sheppard M, et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999; 353:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/81\">",
"      Metso S, Auvinen A, Huhtala H, et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007; 109:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/82\">",
"      Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998; 338:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/83\">",
"      Metso S, Jaatinen P, Huhtala H, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007; 92:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/84\">",
"      Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/85\">",
"      Flynn RW, Macdonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006; 91:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/86\">",
"      Metso S, Auvinen A, Salmi J, et al. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol (Oxf) 2008; 68:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/87\">",
"      Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004; 89:4229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/7/12410/abstract/88\">",
"      Ceccarelli C, Canale D, Battisti P, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 2006; 65:446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7879 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12410=[""].join("\n");
var outline_f12_7_12410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30632233\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632241\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632249\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632257\">",
"      Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632264\">",
"      Toxic adenoma or multinodular goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632271\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632279\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632286\">",
"      Severe ophthalmopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632293\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632300\">",
"      Low versus high",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632307\">",
"      Fixed versus calculated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632314\">",
"      Dose calculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632321\">",
"      TREATMENT REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632329\">",
"      Pretreatment with thionamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3626419\">",
"      - Candidates for pretreatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30632336\">",
"      - Stopping thionamides pre-radioiodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30632344\">",
"      - When to stop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632352\">",
"      Concurrent treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925861\">",
"      Iodine as adjunctive therapy after radioiodine in Graves&rsquo; disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632360\">",
"      Low-iodine diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632367\">",
"      POST TREATMENT PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632375\">",
"      Household contacts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632383\">",
"      Future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632391\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632413\">",
"      RADIOIODINE RESISTANT GRAVES' HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632421\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632428\">",
"      Radioiodine and ophthalmopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30632435\">",
"      - Comparison trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30632443\">",
"      - Treatment with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632451\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632459\">",
"      Overall mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30632467\">",
"      Gonadal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30632233\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7879|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/2/17454\" title=\"figure 1\">",
"      Kaplan Meier plots ophtha",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/3/14397\" title=\"table 1\">",
"      Precaution requirements after treatments with 131-I hyperthyroid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=related_link\">",
"      Diagnostic approach to and treatment of goiter in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=related_link\">",
"      Pretibial myxedema in autoimmune thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32742?source=related_link\">",
"      Treatment of obstructive or substernal goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_7_12411="Exercise ECG in aortic stenosis";
var content_f12_7_12411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for a positive exercise test in asymptomatic patients with aortic stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Development of dyspnea, angina, or presyncope or syncope, which should lead to stopping of the test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A rise in systolic pressure during exercise of less than 20 mmHg; the test is stopped if the systolic pressure falls more than 10 mmHg with exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to reach 80 percent of the predicted normal level of exercise tolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More than 2 mm horizontal or downsloping ST segment depression compared to baseline that cannot be attributed to other causes; the test is stopped if there is more than 5 mm ST segment depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The development of complex ventricular arrhythmias, such as ventricular tachycardia or more than four ventricular premature beats in succession, which should lead to stopping of the test",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262; and from Iung B, Gohlke-Barwolf C, Tornos P, et al. Eur Heart J 2002; 23:1253.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12411=[""].join("\n");
var outline_f12_7_12411=null;
var title_f12_7_12412="Pharma Rx opioid sd eff";
var content_f12_7_12412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used pharmacologic approaches in the management of opioid side effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Side effect",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"11\">",
"       Constipation",
"      </td>",
"      <td class=\"sublist1_start\">",
"       General approach",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Ensure comfort and convenience for defecation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Rule out impaction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Improve hydration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Avoid adding fiber if the patient is debilitated or nutrition or hydration is poor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pharmacologic approaches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Periodic enemas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Oral therapy usually starts with stimulant laxative (eg, senna), stool softener (docusate), and/or an osmotic laxative (eg, lactulose or propylethylene glycol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; For refractory cases, the initial step is to adjust the doses or change the combination of the usual starting regimen, or add more rapid acting osmotic drug (eg, magnesium citrate)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; For refractory cases, consider second-line approaches (eg, metoclopramide, lubiprostone, tegaserod, colchicine, oral naloxone)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Peripherally-acting opioid antagonist drugs (methylnaltrexone) an option for refractory cases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Somnolence or cognitive impairment",
"      </td>",
"      <td class=\"sublist1_start\">",
"       General approach",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Treatment of potential etiologies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Reduce opioid dose by 25 to 50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pharmacologic approaches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Add psychostimulant (eg, methylphenidate, modafinil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Consider cholinesterase inhibitor (eg, donezepil)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12412=[""].join("\n");
var outline_f12_7_12412=null;
var title_f12_7_12413="ACC AHA Treatment critical limb ischemia";
var content_f12_7_12413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Treatment of critical limb ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement for the following approach to the management of critical limb",
"ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Rapid evaluation and treatment of factors known to increase the risk of primary amputation. These include significant necrosis of weight-bearing parts of the foot in ambulatory patients, an uncorrectable flexion contracture, paresis of the extremity, ischemic rest pain, sepsis, or limited life expectancy due to comorbid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The development of acute limb symptoms in patients at risk for CLI (those with diabetes, neuropathy, chronic renal failure, or infection) is a potential vascular emergency that should be assessed immediately and treated by a specialist in vascular disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Prompt initiation of systemic antibiotics in patients with skin ulceration and evidence of limb infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Evaluation for aneurysmal disease (eg, in the abdominal aorta or popliteal or common femoral artery) in patients with evidence of atheroembolization, such as blue toe syndrome or livedo reticularis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Catheter-based thrombolysis for acute limb ischemia (Rutherford category I or IIa) of less than 14 days duration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Preoperative estimation of cardiovascular risk if open surgical repair is anticipated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; When endovascular treatment or surgery is performed for combined inflow and outflow disease, the inflow lesions should be addressed first. If symptoms or infection persist after inflow revascularization, an outflow revascularization should be performed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; If it is uncertain if there is hemodynamically significant inflow disease, intraarterial pressure should be measured before and after administration of a vasodilator.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with skin breakdown should be referred to a healthcare provider with expertise in wound care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients who have been successfully treated for CLI are at relatively high risk for recurrence. They should be evaluated at least twice yearly by a vascular specialist and be given verbal and written instructions for self-surveillance for recurrence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of benefit for the following modality in the",
"management of critical limb ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Mechanical thrombectomy as adjunctive therapy for acute limb ischemia due to peripheral artery occlusion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or opinion is",
"less well established for the following modalities in the management of",
"critical limb ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Angiogenic growth factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Catheter-based thrombolysis or thrombectomy for acute limb ischemia (Rutherford category IIb) of more than 14 days duration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that the following modalities are not useful in the",
"management of critical limb ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Parenteral pentoxifylline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Oral iloprost.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Surgery or endovascular treatment for severe hypoperfusion (eg, ABI less than 0.4) in the absence of symptoms.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12413=[""].join("\n");
var outline_f12_7_12413=null;
var title_f12_7_12414="Child abuse neglect resources A";
var content_f12_7_12414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57326%7EPEDS%2F69110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57326%7EPEDS%2F69110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child abuse and neglect resources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Child Welfare Information Gateway",
"       </td>",
"       <td rowspan=\"2\">",
"        Child Welfare Information Gateway helps professionals locate information related to child abuse and neglect and related child welfare issues. It is a service of the Children's Bureau, within the Administration on Children, Youth, and Families, Administration for Children and Families, U.S. Department of Health and Human Services.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Bureau/ACYF",
"        <br/>",
"        1250 Maryland Avenue, SW",
"        <br/>",
"        Eighth Floor",
"        <br/>",
"        Washington, DC 20224",
"        <br/>",
"        800.394.3366 or 703.385.7565",
"        <br/>",
"        <a href=\"file://www.childwelfare.gov\" target=\"_blank\">",
"         www.childwelfare.gov",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        American Professional Society on the Abuse of Children (APSAC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The APSAC is a nonprofit organization of professionals who work with maltreated children and their families. Members include professionals working in mental health, child welfare, law enforcement, health care, and prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        940 NE 13th Street CHO 3B--3406",
"        <br/>",
"        Oklahoma City, OK 73104",
"        <br/>",
"        (405) 271-8202",
"        <br/>",
"        <a href=\"file://www.apsac.org\" target=\"_blank\">",
"         www.apsac.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Chadwick Center for Children and Families",
"       </td>",
"       <td rowspan=\"2\">",
"        The Chadwick Center for Children and Families addresses the prevention, investigation, diagnosis, treatment, and prosecution of child maltreatment, and conducts professional education and research.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Hospital and Health Center",
"        <br/>",
"        3020 Children's Way MC 5017",
"        <br/>",
"        San Diego, CA 92123",
"        <br/>",
"        (619) 576-5803",
"        <br/>",
"        <a href=\"file://www.rchsd.org\">",
"         www.rchsd.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Child Welfare League of America (CWLA)",
"       </td>",
"       <td rowspan=\"2\">",
"        The Child Welfare League of America is a federation of public and private non-profit agencies and organizations that serve vulnerable children and youths and their families. CWLA provides training, consultation, and technical assistance to child welfare professionals and agencies while also educating the public about emerging issues affecting abused, neglected, and at-risk children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        440 First St., NW, Third Floor",
"        <br/>",
"        Washington, DC 20001-2085",
"        <br/>",
"        (202) 638-2952",
"        <br/>",
"        <a href=\"file://www.cwla.org\" target=\"_blank\">",
"         www.cwla.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Childhelp USA",
"       </td>",
"       <td rowspan=\"2\">",
"        Childhelp USA is a national organization that provides crisis assistance 24 hours a day, 7 days a week, as well as other counseling and referral services. Childhelp USA is dedicated to meeting the physical, emotional, educational, and spiritual needs of abused and neglected children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15757 North 78th St.",
"        <br/>",
"        Scottsdale, AZ 85260",
"        <br/>",
"        (800) 4-A-CHILD (National Child Abuse Hotline)",
"        <br/>",
"        (480) 922-8212",
"        <br/>",
"        TDD:(800) 2-A-CHILD",
"        <br/>",
"        <a href=\"file://www.childhelpusa.org\" target=\"_blank\">",
"         www.childhelpusa.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Domestic Violence Institute (DVI)",
"       </td>",
"       <td rowspan=\"2\">",
"        The Institute is an international membership organization that provides research, public information, education, and training programs in the area of domestic violence, including child abuse.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 South Steele St.",
"        <br/>",
"        Suite 850",
"        <br/>",
"        Denver, CO 80209",
"        <br/>",
"        (303) 322-1831",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Selected National Organizations Concerned with Child Maltreatment Resource Listing. National Clearinghouse on Child Abuse and Neglect Information (www.calib.com/nccanch/pubs/reslist/rl_dsp.cfm?subjID=10).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child abuse and neglect resources (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Military Family Resource Center (MFRC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The MFRC, funded by the Department of Defense, collects, reviews, processes, and disseminates information on the military family lifestyle and quality of life issues of military members and their families. Program areas include family advocacy (child and spouse abuse), family support, relocation services, child and youth programs, and activities which affect force readiness and quality of life.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1745 Jefferson Davis Hwy",
"        <br/>",
"        CS4, Suite 302, Room 309",
"        <br/>",
"        Arlington, VA 22202-3424",
"        <br/>",
"        (703) 602-4964",
"        <br/>",
"        <a href=\"file://www.militaryhomefront.dod.mil\" target=\"_blank\">",
"         www.militaryhomefront.dod.mil",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Children's Advocacy Center (NCAC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The NCAC provides prevention, intervention, and treatment services to physically and sexually abused children and their families within a child-focused team approach. The NCAC also provides education and training to support the development of Children's Advocacy Centers across the country.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 Westside Sq., Suite 700",
"        <br/>",
"        Huntsville, AL 35801",
"        <br/>",
"        (256) 533-0531",
"        <br/>",
"        <a href=\"file://www.nationalcac.org/\" target=\"_blank\">",
"         www.nationalcac.org/",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Data Archive on Child Abuse and Neglect (NDACAN)",
"       </td>",
"       <td rowspan=\"2\">",
"        The mission of NDACAN is to facilitate the secondary analysis of research data relevant to the study of child abuse and neglect. By making data available to a larger number of researchers, NDACAN seeks to provide a relatively inexpensive and scientifically productive means for researchers to explore important issues in the child maltreatment field.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family Life Development Center",
"        <br/>",
"        Beebe Hall - FLDC",
"        <br/>",
"        Cornell University",
"        <br/>",
"        Ithaca, NY 14853-4401",
"        <br/>",
"        (607) 255-7799",
"        <br/>",
"        <a href=\"file://www.ndacan.cornell.edu\" target=\"_blank\">",
"         www.ndacan.cornell.edu",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Indian Child Welfare Association (NICWA)",
"       </td>",
"       <td rowspan=\"2\">",
"        The NICWA is the only Native American organization focused specifically on issues of child abuse and neglect and Tribal capacity to prevent and respond effectively to these problems. NICWA sponsors a national conference; provides publications and information packets and technical assistance; and maintains a library for information on child welfare and child abuse and neglect that is culturally relevant and useful to the American Indian population.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5100 SW Macadam Ave., Suite 300",
"        <br/>",
"        Portland, OR 97201",
"        <br/>",
"        (503) 222-4044",
"        <br/>",
"        <a href=\"file://www.nicwa.org\" target=\"_blank\">",
"         www.nicwa.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Prevent Child Abuse America",
"       </td>",
"       <td rowspan=\"2\">",
"        Prevent Child Abuse America promotes healthy parenting and community involvement as effective strategies for preventing all forms of child abuse. The organization's nationwide network of chapters and local affiliates work to implement direct service programs in hundreds of communities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 S. Michigan Ave., 17th Floor",
"        <br/>",
"        Chicago, IL 60604-2404",
"        <br/>",
"        (800) CHILDREN",
"        <br/>",
"        (312) 663-3520",
"        <br/>",
"        <a href=\"file://www.preventchildabuse.org\" target=\"_blank\">",
"         www.preventchildabuse.org",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Selected National Organizations Concerned with Child Maltreatment Resource Listing. National Clearinghouse on Child Abuse and Neglect Information (www.calib.com/nccanch/pubs/reslist/rl_dsp.cfm?subjID=10).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12414=[""].join("\n");
var outline_f12_7_12414=null;
var title_f12_7_12415="Bilirubin synthesis";
var content_f12_7_12415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilirubin synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 356px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conversion of heme to biliverdin and then bilirubin. Heme ring-opening at the alpha-carbon bridge of heme is catalyzed by heme oxygenase, resulting in the formation of biliverdin. This is followed by reduction of biliverdin to bilirubin in a reaction catalyzed by biliverdin reductase.",
"    <div class=\"footnotes\">",
"     NADH: reduced nicotinamide adenine dinucleotide; NADPH: reduced nicotinamide adenine dinucleotide phosphate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_7_12415=[""].join("\n");
var outline_f12_7_12415=null;
